<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants - Bruschettini, M - 2020 | Cochrane Library</title> <meta content="Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants - Bruschettini, M - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013202.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants - Bruschettini, M - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013202.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013202.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants" name="citation_title"/> <meta content="Matteo Bruschettini" name="citation_author"/> <meta content="matteo.bruschettini@med.lu.se" name="citation_author_email"/> <meta content="Olga Romantsik" name="citation_author"/> <meta content="Lund University, Skåne University Hospital" name="citation_author_institution"/> <meta content="Alvaro Moreira" name="citation_author"/> <meta content="University of Texas Health Science Center at San Antonio" name="citation_author_institution"/> <meta content="David Ley" name="citation_author"/> <meta content="Lund University, Skåne University Hospital" name="citation_author_institution"/> <meta content="Bernard Thébaud" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD013202.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/08/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013202.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013202.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013202.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Inflammatory Agents [therapeutic use]; Fetal Blood [cytology]; Hydrocortisone [therapeutic use]; Hypothermia, Induced; Hypoxia-Ischemia, Brain [complications, mortality, *therapy]; *Stem Cell Transplantation" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013202.pub2&amp;doi=10.1002/14651858.CD013202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013202\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013202\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013202.pub2",title:"Stem cell\\u2010based interventions for the prevention of morbidity and mortality following hypoxic\\u2010ischaemic encephalopathy in newborn infants",firstPublishedDate:"Aug 19, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013202.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013202.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013202.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013202.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013202.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013202.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013202.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013202.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013202.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013202.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4104 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013202.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-sec-0065"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-sec-0059"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/appendices#CD013202-sec-0069"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#CD013202-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Matteo Bruschettini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#CD013202-cr-0005">Olga Romantsik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#CD013202-cr-0006">Alvaro Moreira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#CD013202-cr-0007">David Ley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information#CD013202-cr-0008">Bernard Thébaud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information/en#CD013202-sec-0075">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 August 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013202.pub2">https://doi.org/10.1002/14651858.CD013202.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013202-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013202-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013202-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013202-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013202-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013202-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013202-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013202-abs-0001" lang="en"> <section id="CD013202-sec-0001"> <h3 class="title" id="CD013202-sec-0001">Background</h3> <p>Hypoxic‐ischaemic encephalopathy (HIE) is a leading cause of mortality and long‐term neurological sequelae, affecting thousands of children worldwide. Current therapies to treat HIE are limited to cooling. Stem cell‐based therapies offer a potential therapeutic approach to repair or regenerate injured brain tissue. These preclinical findings have now culminated in ongoing human neonatal trials. </p> </section> <section id="CD013202-sec-0002"> <h3 class="title" id="CD013202-sec-0002">Objectives</h3> <p>To determine the efficacy and safety of stem cell‐based interventions for the treatment of hypoxic‐ischaemic encephalopathy (HIE) in newborn infants. </p> </section> <section id="CD013202-sec-0003"> <h3 class="title" id="CD013202-sec-0003">Search methods</h3> <p>We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 5), MEDLINE via PubMed (1966 to 8 June 2020), Embase (1980 to 8 June 2020), and CINAHL (1982 to 8 June 2020). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi‐randomised trials. </p> </section> <section id="CD013202-sec-0004"> <h3 class="title" id="CD013202-sec-0004">Selection criteria</h3> <p>Randomised controlled trials, quasi‐randomised controlled trials and cluster trials comparing 1) stem cell‐based interventions (any type) compared to control (placebo or no treatment); 2) use of mesenchymal stem/stromal cells (MSCs) of type (e.g. number of doses or passages) or source (e.g. autologous versus allogeneic, or bone marrow versus cord) versus MSCs of other type or source; 3) use of stem cell‐based interventions other than MSCs of type (e.g. mononuclear cells, oligodendrocyte progenitor cells, neural stem cells, hematopoietic stem cells, and inducible pluripotent stem cells) or source (e.g. autologous versus allogeneic, or bone marrow versus cord) versus stem cell‐based interventions other than MSCs of other type or source; or 4) MSCs versus stem cell‐based interventions other than MSCs. </p> </section> <section id="CD013202-sec-0005"> <h3 class="title" id="CD013202-sec-0005">Data collection and analysis</h3> <p>For each of the included trials, two authors independently planned to extract data (e.g. number of participants, birth weight, gestational age, type and source of MSCs or other stem cell‐based interventions) and assess the risk of bias (e.g. adequacy of randomisation, blinding, completeness of follow‐up). The primary outcomes considered in this review are all‐cause neonatal mortality, major neurodevelopmental disability, death or major neurodevelopmental disability assessed at 18 to 24 months of age. We planned to use the GRADE approach to assess the quality of evidence. </p> </section> <section id="CD013202-sec-0006"> <h3 class="title" id="CD013202-sec-0006">Main results</h3> <p>Our search strategy yielded 616 references. Two review authors independently assessed all references for inclusion. We did not find any completed studies for inclusion. Fifteen RCTs are currently registered and ongoing. We describe the three studies we excluded. </p> </section> <section id="CD013202-sec-0007"> <h3 class="title" id="CD013202-sec-0007">Authors' conclusions</h3> <p>There is currently no evidence from randomised trials that assesses the benefit or harms of stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013202-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013202-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013202-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013202-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013202-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013202-abs-0010">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013202-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013202-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013202-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013202-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013202-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013202-abs-0002" lang="en"> <h3>Stem cell‐based therapies following poor brain oxygenation at birth (hypoxic‐ischaemic encephalopathy) in newborns </h3> <p><b>Review question</b> </p> <p>Do stem cell‐based therapies save the lives, or improve the long‐term development, of newborns who have poor brain oxygenation at birth ('hypoxic‐ischaemic encephalopathy')? </p> <p><b>Background</b> </p> <p>Lack of oxygen at birth may damage the brain of the newborn. Babies with less severe brain damage may make a full recovery or only have mild problems. For other babies with more serious damage, this may lead to death or to problems later in life. For instance, some of these babies develop cerebral palsy, intellectual disabilities, or other problems. We currently have  only cooling as an approach to treat this condition. The aim of this review was to assess if stem cell‐based therapies could reduce death and improve the long‐term development of newborns with poor brain oxygenation at birth. During stem cell‐based therapy, stem cells are given to the baby, for instance through injections. These stem cells may have come from humans or animals and may have been taken from cord blood, bone marrow or other parts of the body. These cells then repair the brain cells that the lack of oxygen has damaged. </p> <p><b>Key results</b> </p> <p>We were not able to include any studies in our review. We identified three potential studies, but we excluded them due to the way they were designed which meant that their results could not answer our review question (phase 1 studies). Fifteen studies are ongoing. </p> <p><b>How up to date is this review?</b> </p> <p>We searched for studies that were available up to June 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013202-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013202-sec-0065"></div> <h3 class="title" id="CD013202-sec-0066">Implications for practice</h3> <section id="CD013202-sec-0066"> <p>There is currently no evidence from randomised trials that assesses the benefit or harms of stem cell‐based interventions for the prevention of morbidity and mortality following hypoxic‐ischaemic encephalopathy in newborn infants. </p> </section> <h3 class="title" id="CD013202-sec-0067">Implications for research</h3> <section id="CD013202-sec-0067"> <p>Findings from a meta‐analysis of preclinical studies on hypoxic‐ischaemic encephalopathy indicate that treatment with mesenchymal stromal cells might improve neurologic function (<a href="./references#CD013202-bbs2-0022" title="ArchambaultJ , MoreiraA , McDanielD , WinterL , SunL , HornsbyP . Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: a systematic review and meta-analysis of preclinical studies. PloS One2017;12(12):e0189895. [DOI: 10.1371/journal.pone.0189895] [PMID: 29261798]">Archambault 2017</a>). Although this review was limited by high heterogeneity, results can be useful for future design of clinical trials. For instance, a recent review on the use of mesenchymal stem cells in the treatment of ischaemic heart disease highlighted some potential reasons for a lacklustre response in clinical trials: timing of cell delivery, delivery method, and cell processing (<a href="./references#CD013202-bbs2-0152" title="WardMR , AbadehA , ConnellyKA . Concise review: rational use of mesenchymal stem cells in the treatment of ischemic heart disease. Stem Cells Translational Medicine2018;7(7):543-50. [DOI: 10.1002/sctm.17-0210] [PMID: 29665255]">Ward 2018</a>). Thus, clinical trials should focus on standardising some of these variables to optimise the therapeutic potential of stem cell‐based interventions. In doing so, the scientific community would be able to improve the impact of the results (by increased power) which would allow for a more unified interpretation of findings from clinical trials. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013202-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013202-sec-0008"></div> <section id="CD013202-sec-0009"> <h3 class="title" id="CD013202-sec-0009">Description of the condition</h3> <p>Hypoxic‐ischaemic encephalopathy (HIE) is a leading cause of mortality and long‐term neurological sequelae, affecting thousands of children in both developed and developing countries (<a href="./references#CD013202-bbs2-0082" title="LeeACC , KozukiN , BlencoweH , VosT , BahalimA , DarmstadtGL , et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatric Research2013;74(Suppl 1):50-72. [DOI: 10.1038/pr.2013.206] [PMID: 24366463]">Lee 2013</a>). Every year 1.15 million infants develop HIE, with 96% born in low‐ and middle‐income countries. Up to 25% of neonates with HIE die and around 35% have long‐term neurodevelopmental sequelae (<a href="./references#CD013202-bbs2-0082" title="LeeACC , KozukiN , BlencoweH , VosT , BahalimA , DarmstadtGL , et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatric Research2013;74(Suppl 1):50-72. [DOI: 10.1038/pr.2013.206] [PMID: 24366463]">Lee 2013</a>). Severity of HIE is scored in three stages: Stage I (Sarnat 1) – mild; Stage II (Sarnat 2) – moderate; Stage III (Sarnat 3) – severe (<a href="./references#CD013202-bbs2-0129" title="SarnatHB , SarnatMS . Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Archives of Neurology1976;33(10):696-705. [PMID: 987769]">Sarnat 1976</a>). Standard management in neonatal intensive care units consists of providing supportive care to maintain cerebral perfusion and metabolic balance. The only effective intervention is therapeutic hypothermia, which reduces mortality and improves neurocognitive outcome of newborns at 18 months of age (<a href="./references#CD013202-bbs2-0046" title="EdwardsAD , BrocklehurstP , GunnAJ , HallidayH , JuszczakE , LeveneM , et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ (Clinical Research Ed.)2010;340:c363. [PMID: 20144981]">Edwards 2010</a>; <a href="./references#CD013202-bbs2-0074" title="JacobsSE , BergM , HuntR , Tarnow-MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD003311. [DOI: 10.1002/14651858.CD003311.pub3]">Jacobs 2013</a>). The lower brain temperature induced by therapeutic hypothermia may decrease brain baseline metabolism and energy demand (<a href="./references#CD013202-bbs2-0104" title="OwjiZP , GilbertG , Saint-MartinC , WintermarkP . Brain temperature is increased during the first days of life in asphyxiated newborns: developing brain injury despite hypothermia treatment. AJNR. American Journal of Neuroradiology2017;38(11):2180-6. [PMID: 28860214]">Owji 2017</a>; <a href="./references#CD013202-bbs2-0114" title="PfisterRH , SollRF . Hypothermia for the treatment of infants with hypoxic-ischemic encephalopathy. Journal of Perinatology2010;30 Suppl:S82-7. [PMID: 20877413]">Pfister 2010</a>; <a href="./references#CD013202-bbs2-0119" title="PoldermanKH . Induced hypothermia and fever control for prevention and treatment of neurological injuries. Lancet2008;371(9628):1955-69. [PMID: 18539227]">Polderman 2008</a>). The mechanisms include reduction of apoptosis, mitochondrial dysfunction, and free radical production; decreased permeability of blood‐brain barrier; and mitigation of reperfusion injury and neuro‐inflammation (<a href="./references#CD013202-bbs2-0057" title="GossJR , StyrenSD , MillerPD , KochanekPM , PalmerAM , MarionDW , et al. Hypothermia attenuates the normal increase in interleukin 1 beta RNA and nerve growth factor following traumatic brain injury in the rat. Journal of Neurotrauma1995;12(2):159-67. [PMID: 7629862]">Goss 1995</a>; <a href="./references#CD013202-bbs2-0062" title="GunnAJ , GunnTR , deHaanHH , WilliamsCE , GluckmanPD . Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal lambs. Journal of Clinical Investigation1997;99(2):248-56. [PMID: 9005993]">Gunn 1997</a>; <a href="./references#CD013202-bbs2-0063" title="GunnAJ , GunnTR . The 'pharmacology' of neuronal rescue with cerebral hypothermia. Early Human Development1998;53(1):19-35. [PMID: 10193924]">Gunn 1998</a>; <a href="./references#CD013202-bbs2-0064" title="HaalandK , LobergEM , SteenPA , ThoresenM . Posthypoxic hypothermia in newborn piglets. Pediatric Research1997;41(4 Pt 1):505-12. [PMID: 9098852]">Haaland 1997</a>; <a href="./references#CD013202-bbs2-0072" title='IwataO , IwataS , ThorntonJS , De VitaE , BainbridgeA , HerbertL , et al. "Therapeutic time window" duration decreases with increasing severity of cerebral hypoxia-ischaemia under normothermia and delayed hypothermia in newborn piglets. Brain Research2007;1154:173-80. [PMID: 17475224]'>Iwata 2007</a>; <a href="./references#CD013202-bbs2-0125" title="RothwellNJ , StrijbosPJ . Cytokines in neurodegeneration and repair. International Journal of Developmental Neuroscience1995;13(3-4):179-85. [PMID: 7572274]">Rothwell 1995</a>; <a href="./references#CD013202-bbs2-0133" title="SilversteinFS , BarksJD , HaganP , LiuXH , IvackoJ , SzaflarskiJ . Cytokines and perinatal brain injury. Neurochemistry International1997;30(4-5):375-83. [PMID: 9106251]">Silverstein 1997</a>; <a href="./references#CD013202-bbs2-0138" title="ThoresenM , PenriceJ , LorekA , CadyEB , WylezinskaM , KirkbrideV , et al. Mild hypothermia after severe transient hypoxia-ischemia ameliorates delayed cerebral energy failure in the newborn piglet. Pediatric Research1995;37(5):667-70. [PMID: 7603788]">Thoresen 1995</a>). However, treatment should be started during the latent phase of brain injury, which extends up to six hours from the primary brain insult (<a href="./references#CD013202-bbs2-0054" title="GluckmanPD , WilliamsCE . When and why do brain cells die?Developmental Medicine and Child Neurology1992;34(11):1010-4. [PMID: 1358734]">Gluckman 1992</a>), to avoid reperfusion injury (<a href="./references#CD013202-bbs2-0062" title="GunnAJ , GunnTR , deHaanHH , WilliamsCE , GluckmanPD . Dramatic neuronal rescue with prolonged selective head cooling after ischemia in fetal lambs. Journal of Clinical Investigation1997;99(2):248-56. [PMID: 9005993]">Gunn 1997</a>; <a href="./references#CD013202-bbs2-0159" title="ZhaoW , RichardsonJS , MombourquetteMJ , WeilJA , IjazS , ShuaibA . Neuroprotective effects of hypothermia and U-78517F in cerebral ischemia are due to reducing oxygen-based free radicals: an electron paramagnetic resonance study with gerbils. Journal of Neuroscience Research1996;45(3):282-8. [PMID: 8841989]">Zhao 1996</a>). Furthermore, the duration of treatment should be long enough to mitigate a secondary phase of neural injury with cytotoxic cell oedema, apoptosis, accumulation of extracellular excitotoxins, and delayed seizures due to reperfusion (<a href="./references#CD013202-bbs2-0134" title="SirimanneES , BlumbergRM , BossanoD , GunningM , EdwardsAD , GluckmanPD , et al. The effect of prolonged modification of cerebral temperature on outcome after hypoxic-ischemic brain injury in the infant rat. Pediatric Research1996;39(4 Pt 1):591-7. [PMID: 8848330]">Sirimanne 1996</a>; <a href="./references#CD013202-bbs2-0137" title="TanWK , WilliamsCE , DuringMJ , MallardCE , GunningMI , GunnAJ , et al. Accumulation of cytotoxins during the development of seizures and edema after hypoxic-ischemic injury in late gestation fetal sheep. Pediatric Research1996;39(5):791-7. [PMID: 8726230]">Tan 1996</a>; <a href="./references#CD013202-bbs2-0153" title="WilliamsCE , GunnA , GluckmanPD . Time course of intracellular edema and epileptiform activity following prenatal cerebral ischemia in sheep. Stroke1991;22(4):516-21. [PMID: 2024281]">Williams 1991</a>). Thus, hypothermia should cover the whole reperfusion phase of brain injury and last 72 hours (<a href="./references#CD013202-bbs2-0156" title="WyllieJ , PerlmanJM , KattwinkelJ , WyckoffMH , AzizK , GuinsburgR , et al. Part 7: neonatal resuscitation: 2015 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation2015;95:e169-201. [PMID: 26477424]">Wyllie 2015</a>). </p> <p>Additional therapies for HIE are under investigation and include erythropoietin, allopurinol, xenon, topiramate, and magnesium sulphate. Erythropoietin has anti‐inflammatory, antioxidative, antiapoptotic, and antiexcitotoxic properties (<a href="./references#CD013202-bbs2-0147" title="VillaP , BiginiP , MenniniT , AgnelloD , LaragioneT , CagnottoA , et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. Journal of Experimental Medicine2003;198(6):971-5. [PMID: 12975460]">Villa 2003</a>). In addition, it may promote neurogenesis and angiogenesis (<a href="./references#CD013202-bbs2-0149" title="WangL , ZhangZ , WangY , ZhangR , ChoppM . Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke2004;35(7):1732-7. [PMID: 15178821]">Wang 2004</a>). In animal models of HIE, erythropoietin attenuates brain damage, and improves learning memory (<a href="./references#CD013202-bbs2-0055" title="GonzalezFF , AbelR , AlmliCR , MuD , WendlandM , FerrieroDM . Erythropoietin sustains cognitive function and brain volume after neonatal stroke. Developmental Neuroscience2009;31(5):403-11. [PMID: 19672069]">Gonzalez 2009</a>; <a href="./references#CD013202-bbs2-0080" title="KumralA , UysalN , TugyanK , SonmezA , YilmazO , GokmenN , et al. Erythropoietin improves long-term spatial memory deficits and brain injury following neonatal hypoxia-ischemia in rats. Behavioural Brain Research2004;153(1):77-86. [PMID: 15219709]">Kumral 2004</a>; <a href="./references#CD013202-bbs2-0154" title="WuYW , BauerLA , BallardRA , FerrieroDM , GliddenDV , MayockDE , et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics2012;130(4):683-91. [PMID: 23008465]">Wu 2012</a>). These data seem to be confirmed in small clinical trials (<a href="./references#CD013202-bbs2-0048" title="ElmahdyH , El-MashadAR , El-BahrawyH , El-GoharyT , El-BarbaryA , AlyH . Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics2010;125(5):e1135-42. [PMID: 20385632]">Elmahdy 2010</a>; <a href="./references#CD013202-bbs2-0123" title="RogersEE , BonifacioSL , GlassHC , JuulSE , ChangT , MayockDE , et al. Erythropoietin and hypothermia for hypoxic-ischemic encephalopathy. Pediatric Neurology2014;51(5):657-62. [PMID: 25439577]">Rogers 2014</a>; <a href="./references#CD013202-bbs2-0160" title="ZhuC , KangW , XuF , ChengX , ZhangZ , JiaL , et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics2009;124(2):e218-26. [PMID: 19651565]">Zhu 2009</a>). Allopurinol may be neuroprotective through direct scavenging of hydroxyl radicals and neutralizing non‐protein‐bound iron (<a href="./references#CD013202-bbs2-0112" title="Peeters-ScholteC , BraunK , KosterJ , KopsN , BlomgrenK , BuonocoreG , et al. Effects of allopurinol and deferoxamine on reperfusion injury of the brain in newborn piglets after neonatal hypoxia-ischemia. Pediatric Research2003;54(4):516-22. [PMID: 12815112]">Peeters‐Scholte 2003</a>). Animal studies showed that allopurinol might be neuroprotective (<a href="./references#CD013202-bbs2-0106" title="PalmerC , TowfighiJ , RobertsRL , HeitjanDF . Allopurinol administered after inducing hypoxia-ischemia reduces brain injury in 7-day-old rats. Pediatric Research1993;33(4 Pt 1):405-11. [PMID: 8479823]">Palmer 1993</a>). Furthermore, its administration to term infants affected by HIE might improve neurocognitive outcome at four to eight years of age (<a href="./references#CD013202-bbs2-0076" title="Kaandorp JJ,  van BelF ,  VeenS ,  DerksJB ,  GroenendaalF ,  RijkenM , et al. Long-term neuroprotective effects of allopurinol after moderate perinatal asphyxia: follow-up of two randomised controlled trials. Archives of Disease in Childhood. Fetal and Neonatal Edition2012;97(3):F162-6. [DOI: 10.1136/archdischild-2011-300356] [PMID: 22102633]">Kaandorp 2012</a>). Xenon has been reported to decrease brain injury in animal studies (<a href="./references#CD013202-bbs2-0039" title="DavidHN , HaelewynB , RouillonC , LecoqM , ChazalvielL , ApiouG , et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB Journal2008;22(4):1275-86. [PMID: 18024836]">David 2008</a>; <a href="./references#CD013202-bbs2-0087" title="MaD , HossainM , ChowA , ArshadM , BattsonRM , SandersRD , et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Annals of Neurology2005;58(2):182-93. [PMID: 16049939]">Ma 2005</a>), with additional efficacy when combined with hypothermia (<a href="./references#CD013202-bbs2-0068" title="HobbsC , ThoresenM , TuckerA , AquilinaK , ChakkarapaniE , DingleyJ . Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke2008;39(4):1307-13. [PMID: 18309163]">Hobbs 2008</a>; <a href="./references#CD013202-bbs2-0139" title="ThoresenM , HobbsCE , WoodT , ChakkarapaniE , DingleyJ . Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. Journal of Cerebral Blood Flow and Metabolism2009;29(4):707-14. [PMID: 19142190]">Thoresen 2009</a>). In one phase 2 clinical trial, xenon seemed to be safe (<a href="./references#CD013202-bbs2-0042" title="DingleyJ , TooleyJ , LiuX , Scull-BrownE , ElstadM , ChakkarapaniE , et al. Xenon ventilation during therapeutic hypothermia in neonatal encephalopathy: a feasibility study. Pediatrics2014;133(5):809-18. [PMID: 24777219]">Dingley 2014</a>). Topiramate may reduce brain damage, decrease the rate of apoptosis, diminish the infarcted area, and improved neurological outcome in animal models of HIE (<a href="./references#CD013202-bbs2-0102" title="NohMR , KimSK , SunW , ParkSK , ChoiHC , LimJH , et al. Neuroprotective effect of topiramate on hypoxic ischemic brain injury in neonatal rats. Experimental Neurology2006;201(2):470-8. [PMID: 16884714]">Noh 2006</a>; <a href="./references#CD013202-bbs2-0105" title="OzyenerF , CetinkayaM , AlkanT , GorenB , KafaIM , KurtMA , et al. Neuroprotective effects of melatonin administered alone or in combination with topiramate in neonatal hypoxic-ischemic rat model. Restorative Neurology and Neuroscience2012;30(5):435-44. [PMID: 22751353]">Ozyener 2012</a>; <a href="./references#CD013202-bbs2-0132" title="SfaelloI , BaudO , ArzimanoglouA , GressensP . Topiramate prevents excitotoxic damage in the newborn rodent brain. Neurobiology of Disease2005;20(3):837-48. [PMID: 16009561]">Sfaello 2005</a>). One ongoing trial aims to investigate the effects of topiramate on full‐term neonates with HIE undergoing hypothermia (<a href="./references#CD013202-bbs2-0098" title="NCT01765218. Topiramate in neonates receiving whole body cooling for hypoxic ischemic encephalopathy [Topiramate as an adjuvant to therapeutic hypothermia for infants with hypoxic ischemic encephalopathy]. clinicaltrials.gov/ct2/show/NCT01765218 (first received 10 January 2013).">NCT01765218</a>). There are controversies regarding the neuroprotective role of magnesium sulphate in brain damage in term and late preterm infants (<a href="./references#CD013202-bbs2-0051" title="GalinskyR , BennetL , GroenendaalF , LearCA , TanS , vanBelF , et al. Magnesium is not consistently neuroprotective for perinatal hypoxia-ischemia in term-equivalent models in preclinical studies: a systematic review. Developmental Neuroscience2014;36(2):73-82. [PMID: 24854050]">Galinsky 2014</a>; <a href="./references#CD013202-bbs2-0136" title="TaginM , ShahPS , LeeKS . Magnesium for newborns with hypoxic-ischemic encephalopathy: a systematic review and meta-analysis. Journal of Perinatology2013;33(9):663-9. [PMID: 23743671]">Tagin 2013</a>). The data from animal studies show lack of beneficial neuroprotective effect following HIE (<a href="./references#CD013202-bbs2-0040" title="deHaanHH , GunnAJ , WilliamsCE , HeymannMA , GluckmanPD . Magnesium sulfate therapy during asphyxia in near-term fetal lambs does not compromise the fetus but does not reduce cerebral injury. American Journal of Obstetrics and Gynecology1997;176(1 Pt 1):18-27. [PMID: 9024083]">de Haan 1997</a>; <a href="./references#CD013202-bbs2-0060" title="GreenwoodK , CoxP , MehmetH , PenriceJ , AmessPN , CadyEB , et al. Magnesium sulfate treatment after transient hypoxia-ischemia in the newborn piglet does not protect against cerebral damage. Pediatric Research2000;48(3):346-50. [PMID: 10960501]">Greenwood 2000</a>; <a href="./references#CD013202-bbs2-0113" title="PenriceJ , AmessPN , PunwaniS , WylezinskaM , TyszczukL , D'SouzaP , et al. Magnesium sulfate after transient hypoxia-ischemia fails to prevent delayed cerebral energy failure in the newborn piglet. Pediatric Research1997;41(3):443-7. [PMID: 9078550]">Penrice 1997</a>). There is an ongoing clinical trial on magnesium sulphate during therapeutic hypothermia in term neonates with HIE (<a href="./references#CD013202-bbs2-0097" title="NCT01646619. Efficacy study of hypothermia plus magnesium sulphate (MgSO4) in the management of term and near term babies with hypoxic ischemic encephalopathy (MagCool) [A multicenter randomized controlled trial of therapeutic hypothermia plus magnesium sulphate (MgSO4) versus therapeutic hypothermia plus placebo in the management of term and near term babies with hypoxic ischemic encephalopathy]. clinicaltrials.gov/ct2/show/NCT01646619 (first received 20 July 2012).">NCT01646619</a>). </p> </section> <section id="CD013202-sec-0010"> <h3 class="title" id="CD013202-sec-0010">Description of the intervention</h3> <p>Mesenchymal stem/stromal cells (MSCs) have emerged as exciting and new therapeutic agents that could potentially ameliorate HIE (<a href="./references#CD013202-bbs2-0096" title="NabetaniM , ShintakuH , HamazakiT . Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2018;83(1-2):356-63. [PMID: 29016557]">Nabetani 2018</a>). MSCs are the most commonly used regenerative cells in clinical trials due to their relatively safe profile, ease of isolation/propagation, ability to reduce inflammation and oxidative stress, restore energy failure, and decrease cell apoptosis (<a href="./references#CD013202-bbs2-0141" title="TrounsonA , McdonaldC . Stem cell therapies in clinical trials: progress and challenges. Stem Cell2015;17(1):11-22.">Trounson 2015</a>). The International Society for Cellular Therapy defines cells as MSCs by the following criteria: adhere to plastic in standard culture conditions; express specific surface antigen markers; and have the capacity for multipotent differentiation (<a href="./references#CD013202-bbs2-0043" title="DominiciM , Le BlancK , MuellerI , Slaper-CortenbachI , MariniF , KrauseD , et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy2006;8(4):315-7. [DOI: 10.1080/14653240600855905] [PMID: 16923606]">Dominici 2006</a>). Although MSCs are ubiquitously used in regenerative studies, additional stem cell‐based therapies (built on what are collectively referred to as 'regenerative cells') are also under consideration. For instance, mononuclear cells, oligodendrocyte progenitor cells, neural stem cells, hematopoietic stem cells, endothelial cells, and inducible pluripotent stem cells have demonstrated efficacy in animal models of brain injury (<a href="./references#CD013202-bbs2-0116" title="Pimentel-CoelhoPM , Rosado-de-CastroPH , da FonsecaLM , Mendez-OteroR . Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2012;71(4 Pt 2):464-73. [PMID: 22430382]">Pimentel‐Coelho 2012</a>). Furthermore, one ongoing clinical trial is evaluating the efficacy of autologous umbilical cord blood (which contains a combination of MSCs, haematopoietic stem cells, and other mononuclear cells) as a treatment for HIE (<a href="./references#CD013202-bbs2-0016" title="NCT02612155. A multi-site study of autologous cord blood cells for hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/nct02612155 (first received 23 November 2015). ">NCT02612155</a>). While inducible pluripotent stem cells are typically obtained from skin cells, they can also be retrieved from blood or MSCs to become a specialized cell, such as a neural stem cell or oligodendrocyte (<a href="./references#CD013202-bbs2-0032" title="CaiJ , LiW , SuH , QinD , YangJ , ZhuF , et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. Journal of Biological Chemistry2010;285(15):11227-34.">Cai 2010</a>). </p> <p>Several factors must be taken into account when optimising regenerative cells. For example, the tissue source, laboratory processing, passage number, dose, frequency, timing, and route of administration are all variables that may affect efficacy (<a href="./references#CD013202-bbs2-0095" title="MöbiusMA , ThebaudB . Stem cells and their mediators – next generation therapy for bronchopulmonary dysplasia. Frontiers in Medicine2015;2:50. [PMID: 26284246]">Möbius 2015</a>). The perinatal period offers an opportune time to collect umbilical cord tissue/blood, amniotic fluid or placental tissue (<a href="./references#CD013202-bbs2-0052" title="GarciaO , WarburtonD . Amniotic fluid stem cell therapy for lung disease. In: AtalaA , MurphyS , editors(s). Perinatal Stem Cells. New York (NY): Springer, 2014:59-66. [DOI: 10.1007/978-1-4939-1118-9_6]">Garcia 2014</a>; <a href="./references#CD013202-bbs2-0111" title="ParoliniO , DeD , RodriguesM , CarusoM . Placental stem/progenitor cells: isolation and characterization. In: Perinatal Stem Cells. New York (NY): Springer, 2014:141-57. [DOI: 10.1007/978-1-4939-1118-9_13]">Parolini 2014</a>; <a href="./references#CD013202-bbs2-0128" title="SanbergPR , EveDJ , BorlonganCV . Umbilical cord blood cells in the repair of central nervous system diseases. In: AtalaA , MurphyS , editors(s). Perinatal Stem Cells. New York (NY): Springer, 2014:269-87. [DOI: 10.1007/978-1-4939-1118-9_25]">Sanberg 2014</a>; <a href="./references#CD013202-bbs2-0135" title="TaghizadehRR , HolzerPW , MarinoT , CetruloKJ , CetruloCL , CetruloCL . Towards clinical applications of umbilical cord derived mesenchymal stem cells. In: AtalaA , MurphyS , editors(s). Perinatal Stem Cells. New York (NY): Springer, 2014:347-59. [DOI: 10.1007/978-1-4939-1118-9_31]">Taghizadeh 2014</a>). These sources, once considered medical waste, offer a vast supply of regenerative cells that are obtained non‐invasively and recognized for their high proliferative rates/differentiation potential, paracrine release of biological factors and low likelihood of mounting an immune response after transplantation (<a href="./references#CD013202-bbs2-0025" title="BatsaliAK , KastrinakiMC , PapadakiHA , PontikoglouC . Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Current Stem Cell Research &amp; Therapy2013;8(2):144-55. [PMID: 23279098]">Batsali 2013</a>; <a href="./references#CD013202-bbs2-0095" title="MöbiusMA , ThebaudB . Stem cells and their mediators – next generation therapy for bronchopulmonary dysplasia. Frontiers in Medicine2015;2:50. [PMID: 26284246]">Möbius 2015</a>; <a href="./references#CD013202-bbs2-0092" title="MoreiraA , AlayliY , BalgiS , WinterC , KahlenbergS , MustafaS , et al. Upcycling umbilical cords: bridging regenerative medicine with neonatology. Journal of Maternal-fetal &amp; Neonatal Medicine2019;32(8):1378-87. [PMID: 29132234]">Moreira 2019</a>; <a href="./references#CD013202-bbs2-0110" title="ParoliniO , AlvianoF , BagnaraGP , BilicG , BühringHJ , EvangelistaM , et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells. Stem Cells2008;26(2):300-11.">Parolini 2008</a>). The therapeutic potential of regenerative cells may also be influenced by different laboratory cell‐processing techniques (e.g. oxygen tension, cell expansion media, passage number, fresh versus cryopreserved cells) (<a href="./references#CD013202-bbs2-0050" title="FreyNV , LazarusHM , GoldsteinSC . Has allogeneic stem cell cryopreservation been given the 'cold shoulder'? An analysis of the pros and cons of using frozen versus fresh stem cell products in allogeneic stem cell transplantation. Bone Marrow Transplantation2006;38(6):399-405. [PMID: 16892075]">Frey 2006</a>; <a href="./references#CD013202-bbs2-0077" title="KaplanA , SackettK , SumstadD , KadidloD , McKennaDH . Impact of starting material (fresh versus cryopreserved marrow) on mesenchymal stem cell culture. Transfusion2017;57(9):2216-9. [PMID: 28653392]">Kaplan 2017</a>; <a href="./references#CD013202-bbs2-0109" title="ParodyR , CaballeroD , Marquez-MalaverFJ , VazquezL , SaldanaR , MadrigalMD , et al. To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors. European Journal of Haematology2013;91(5):448-55. [PMID: 23710624]">Parody 2013</a>). Fewer passages is preferred, as multiple passages may impair cell function (<a href="./references#CD013202-bbs2-0028" title="BellayrIH , CatalanoJG , LababidiS , YangAX , Lo SurdoJL , BauerSR , et al. Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Research &amp; Therapy2014;5(2):59. [DOI: 10.1186/scrt448] [PMID: 24780490]">Bellayr 2014</a>; <a href="./references#CD013202-bbs2-0148" title="WagnerW , HornP , CastoldiM , DiehlmannA , BorkS , SaffrichR , et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PloS One2008;3(5):e2213. [DOI: 10.1371/journal.pone.0002213] [PMID: 18493317]">Wagner 2008</a>). Interestingly, larger amounts of immature haematopoietic progenitors and MSCs with high proliferative potential have been detected in the cord blood of preterm as compared with term infants (<a href="./references#CD013202-bbs2-0118" title="PodestaM , BruschettiniM , CossuC , SabatiniF , DagninoM , RomantsikO , et al. Preterm cord blood contains a higher proportion of immature hematopoietic progenitors compared to term samples. PloS One2015;10(9):e0138680. [DOI: 10.1371/journal.pone.0138680] [PMID: 26417990]">Podesta 2015</a>). In one systematic review of animal models of HIE, neuroprotective dosages of MSCs ranged between 200,000 to 3,500,000 cells, with most of the studies administering a one‐time intracerebral/intranasal dose of cells 72 hours or less after injury (<a href="./references#CD013202-bbs2-0022" title="ArchambaultJ , MoreiraA , McDanielD , WinterL , SunL , HornsbyP . Therapeutic potential of mesenchymal stromal cells for hypoxic ischemic encephalopathy: a systematic review and meta-analysis of preclinical studies. PloS One2017;12(12):e0189895. [DOI: 10.1371/journal.pone.0189895] [PMID: 29261798]">Archambault 2017</a>). </p> <p>Though regenerative cells are characterized by low immunogenicity (<a href="./references#CD013202-bbs2-0053" title="GeblerA , ZabelO , SeligerB . The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine2012;18(2):128-34. [DOI: 10.1016/j.molmed.2011.10.004] [PMID: 22118960]">Gebler 2012</a>), autologous transplantation is likely to be associated with lower risks for infections and immune rejection. Allogeneic transplantation may offer significant practical advantages, however, such as rapid availability of disease‐free products that are generated in a cost‐effective manner (<a href="./references#CD013202-bbs2-0065" title="HareJM , DiFedeDL , RiegerAC , FloreaV , LandinAM , El-KhorazatyJ , et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial. Journal of the American College of Cardiology2017;69(5):526-37. [PMID: 27856208]">Hare 2017</a>). </p> </section> <section id="CD013202-sec-0011"> <h3 class="title" id="CD013202-sec-0011">How the intervention might work</h3> <p>It is currently unknown which regenerative cell(s) promotes the therapeutic effects in HIE; however, we will present a brief overview of the potential role(s) each cell has after neurological injury (see also <a href="#CD013202-tbl-0001">Table 1</a>). </p> <div class="table" id="CD013202-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of regenerative cells</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cell type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Source</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rationale</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mechanism of action</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Preclinical/clinical results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>References</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord tissue/blood; rodent/human bone marrow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safe and feasible in phase 1 RCT for bronchopulmonary dysplasia</p> <p> <ul id="CD013202-list-0001"> <li> <p>Low immunogenicity (low MHC II), easily obtainable, rapid expansion</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0002"> <li> <p>Paracrine release of IGF‐1, EGF, VEGF, BDNF</p> </li> <li> <p>Immunomodulatory: regulate T‐cell, B‐cell function, and production of inflammatory cytokines </p> </li> <li> <p>Mitochondrial transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0003"> <li> <p>Nerve fibre remyelination and axonal regeneration</p> </li> <li> <p>Improve behavioural/motor tests</p> </li> <li> <p>Enhance neural cell proliferation, survival, function</p> </li> <li> <p>Decrease infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0021" title="AhnSY , ChangYS , ParkWS . Stem cells for neonatal brain disorders. Neonatology2016;109(4):377-83. [DOI: 10.1159/000444905] [PMID: 27251746]">Ahn 2016</a>; <a href="./references#CD013202-bbs2-0031" title="BoshuizenMC , SteinbergGK . Stem cell-based immunomodulation after stroke: effects on brain repair processes. Stroke2018;49(6):1563-70.">Boshuizen 2018</a>; <a href="./references#CD013202-bbs2-0035" title="ChoppM , LiY . Treatment of neural injury with marrow stromal cells. Lancet Neurology2002;1(2):92-100. [PMID: 12849513]">Chopp 2002</a>; <a href="./references#CD013202-bbs2-0069" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013202-bbs2-0071" title="IslamMN , DasSR , EminMT , WeiM , SunL , WestphalenK , et al. Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Medicine2012;18(5):759-65.">Islam 2012</a>; <a href="./references#CD013202-bbs2-0085" title="LiuAM , LuG , TsangKS , LiG , WuY , HuangZS , et al. Umbilical cord-derived mesenchymal stem cells with forced expression of hepatocyte growth factor enhance remyelination and functional recovery in a rat intracerebral hemorrhage model. Neurosurgery2010;67(2):357-65; discussion 365-6. [DOI: 10.1227/01.NEU.0000371983.06278.B3] [PMID: 20644422]">Liu 2010</a>; <a href="./references#CD013202-bbs2-0094" title="MurphyMB , MoncivaisK , CaplanAI . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental &amp; Molecular Medicine2013;45:e54. [DOI: 10.1038/emm.2013.94] [PMID: 24232253]">Murphy 2013</a>; <a href="./references#CD013202-bbs2-0107" title="ParkWS , SungSI , AhnSY , SungDK , ImGH , YooHS , et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage. Cell Transplantation2016;25(6):1131-44. [DOI: 10.3727/096368915X689640] [PMID: 26440762]">Park 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MNC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0004"> <li> <p>Readily collected and large supply in cord blood with high plasticity</p> </li> <li> <p>Safe and feasible in phase 1 RCT for hypoxic‐ischaemic encephalopathy</p> </li> <li> <p>Low immunogenicity (minimal HLA matching)</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0005"> <li> <p>Increase expression of BDNF, NGF, VEGF, GDNF</p> </li> <li> <p>Activation of pro‐survival Akt pathway</p> </li> <li> <p>Decrease TNF‐α and increase IL‐10 gene expression</p> </li> <li> <p>Reduce CD4+ T cell infiltration</p> </li> <li> <p>Regulate hedgehog signalling</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0006"> <li> <p>Decrease neuronal apoptosis, astrogliosis, inflammation</p> </li> <li> <p>Improve oligodendrocyte survival</p> </li> <li> <p>Induce axonal growth</p> </li> <li> <p>Improve neurobehavioral outcome</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0023" title="AridasJD , McDonaldCA , PatonMC , YawnoT , SutherlandAE , NitsosI , et al. Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb. Journal of Physiology2016;594(5):1421-35. [DOI: 10.1113/JP271104] [PMID: 26527561]">Aridas 2016</a>; Cotton 2014; <a href="./references#CD013202-bbs2-0049" title="FanCG , ZhangQJ , TangFW , HanZB , WangGS , HanZC . Human umbilical cord blood cells express neurotrophic factors. Neuroscience letters2005;380(3):322-5. [PMID: 15862910]">Fan 2005</a>; <a href="./references#CD013202-bbs2-0089" title="McDonaldCA , PennyTR , PatonMC , SutherlandAE , NekkantiL , YawnoT , et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. Journal of Neuroinflammation2018;15(1):47. [PMID: 29454374]">McDonald 2018</a>; <a href="./references#CD013202-bbs2-0116" title="Pimentel-CoelhoPM , Rosado-de-CastroPH , da FonsecaLM , Mendez-OteroR . Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2012;71(4 Pt 2):464-73. [PMID: 22430382]">Pimentel‐Coelho 2012</a>; <a href="./references#CD013202-bbs2-0126" title="RoweDD , LeonardoCC , HallAA , ShahaduzzamanMD , CollierLA , WillingAE , et al. Cord blood administration induces oligodendrocyte survival through alterations in gene expression. Brain Research2010;1366:172-88. [PMID: 20883670]">Rowe 2010</a>; <a href="./references#CD013202-bbs2-0150" title="WangXL , ZhaoYS , HuMY , SunYQ , ChenYX , BiXH . Umbilical cord blood cells regulate endogenous neural stem cell proliferation via hedgehog signaling in hypoxic ischemic neonatal rats. Brain Research2013;1518:26-35. [PMID: 23632377]">Wang 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rodent/human embryonic stem cell; human NSC derivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0007"> <li> <p>Differentiate into oligodendrocytes (cells highly susceptible to hypoxic‐ischaemic injury) </p> </li> <li> <p>Remyelinate injured axons</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0008"> <li> <p>Diffuse biodistribution along white matter tracts and differentiate into myelin‐sheath‐producing oligodendrocytes </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0009"> <li> <p>Promote myelin sheath formation, NSC proliferation, and inhibit apoptosis</p> </li> <li> <p>Motor recovery following CNS injury</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0034" title="ChenLX , MaSM , ZhangP , FanZC , XiongM , ChengGQ , et al. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury. PloS One2015;10(3):e0115997.">Chen 2015</a>; <a href="./references#CD013202-bbs2-0056" title="GopagondanahalliKR , LiJ , FaheyMC , HuntRW , JenkinG , MillerSL , et al. Preterm hypoxic-ischemic encephalopathy. Frontiers in Pediatrics2016;4:114. [PMID: 27812521]">Gopagondanahalli 2016</a>; <a href="./references#CD013202-bbs2-0079" title="KimTK , ParkD , BanYH , ChaY , AnES , ChoiJ , et al. Improvement by human oligodendrocyte progenitor cells of neurobehavioral disorders in an experimental model of neonatal periventricular leukomalacia. Cell Transplantation2018;27(7):1168-77. [PMID: 29978719]">Kim 2018</a>; <a href="./references#CD013202-bbs2-0088" title="ManleyNC , PriestCA , DenhamJ , Wirth ED 3rd, LebkowskiJS . Human embryonic stem cell-derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Translational Medicine2017;6(10):1917-29. [PMID: 28834391]">Manley 2017</a>; <a href="./references#CD013202-bbs2-0101" title="NiimiY , LevisonSW . Pediatric brain repair from endogenous neural stem cells of the subventricular zone. Pediatric Research2018;83(1-2):385-96. [PMID: 29028220]">Niimi 2018</a>; <a href="./references#CD013202-bbs2-0157" title="XuL , RyuJ , HielH , MenonA , AggarwalA , RhaE , et al. Transplantation of human oligodendrocyte progenitor cells in an animal model of diffuse traumatic axonal injury: survival and differentiation. Stem Cell Research &amp; Therapy2015;6(1):93. [PMID: 25971252]">Xu 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human fetal striatum; human ESC; human iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0010"> <li> <p>Differentiate into cells necessary for brain repair, including: neurons, astrocytes, and oligodendrocytes </p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Low immunogenicity and tumorigenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0011"> <li> <p>Immunomodulation</p> </li> <li> <p>Paracrine secretion of BDNF, VEGF, and EGF</p> </li> <li> <p>Attenuate NF‐κB signalling</p> </li> <li> <p>Upregulate glutamate transport</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0012"> <li> <p>Stimulate survival and migration of endogenous NSCs and neurons</p> </li> <li> <p>Reduce inflammation and reactive oxygen species production</p> </li> <li> <p>Improve axonal growth, motor function, decreased infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0038" title="DaadiMM , KlausnerJQ , BajarB , GoshenI , Lee-MesserC , LeeSY , et al. Optogenetic stimulation of neural grafts enhances neurotransmission and downregulates the inflammatory response in experimental stroke model. Cell Transplantation2016;25(7):1371-80. [PMID: 26132738]">Daadi 2016</a>; <a href="./references#CD013202-bbs2-0070" title="HuangL , ZhangL . Neural stem cell therapies and hypoxic-ischemic brain injury. Progress in Neurobiology 2018 May 21 [Epub ahead of print]. [DOI: 10.1016/j.pneurobio.2018.05.004] [PMID: 29758244]">Huang 2018</a>; <a href="./references#CD013202-bbs2-0075" title="JiG , LiuM , ZhaoXF , LiuXY , GuoQL , GuanZF , et al. NF-kappaB signaling is involved in the effects of intranasally engrafted human neural stem cells on neurofunctional improvements in neonatal rat hypoxic-ischemic encephalopathy. CNS Neuroscience &amp; Therapeutics2015;21(12):926-35. [PMID: 26255634]">Ji 2015</a>; <a href="./references#CD013202-bbs2-0090" title="MineY , TatarishviliJ , OkiK , MonniE , KokaiaZ , LindvallO . Grafted human neural stem cells enhance several steps of endogenous neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiology of Disease2013;52:191-203. [PMID: 23276704]">Mine 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0013"> <li> <p>Paracrine release of neurotrophic factors</p> </li> <li> <p>Multipotent capacity and ability to transdifferentiate into neuronal cells</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0014"> <li> <p>Reduce microglial cells and T lymphocytes</p> </li> <li> <p>Secrete VEGF, HGF, IGF‐1</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0015"> <li> <p>Decrease infarct size and maintains cerebral blood flow</p> </li> <li> <p>Enhance axonal growth</p> </li> <li> <p>Ameliorate neuronal apoptosis and post‐ischaemic inflammation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0130" title="SchwartingS , LitwakS , HaoW , BahrM , WeiseJ , NeumannH . Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke2008;39(10):2867-75. [PMID: 18658037]">Schwarting 2008</a>; <a href="./references#CD013202-bbs2-0142" title="TsujiM , TaguchiA , OhshimaM , KasaharaY , SatoY , TsudaH , et al. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience2014;263:148-58. [PMID: 24444827]">Tsuji 2014</a>; <a href="./references#CD013202-bbs2-0146" title="VerinaT , FatemiA , JohnstonMV , ComiAM . Pluripotent possibilities: human umbilical cord blood cell treatment after neonatal brain injury. Pediatric Neurology2013;48(5):346-54. [PMID: 23583051]">Verina 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EPC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical vein; human umbilical cord blood; human adipose stem cell; human iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0016"> <li> <p>Umbilical‐cord‐derived EPCs have higher regenerative potential than adult bone marrow‐derived EPCs </p> </li> <li> <p>Endothelial cell protection, repair, angiogenesis</p> </li> <li> <p>Low immunogenicity</p> </li> <li> <p>Paracrine release of regenerative factors</p> </li> <li> <p>Autologous administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0017"> <li> <p>Anti‐inflammatory effects: reduce CD4<sup>+</sup> infiltration to the brain </p> </li> <li> <p>Activation of PI3/Akt pathway</p> </li> <li> <p>Axonal growth: BDNF secretion</p> </li> <li> <p>Angiogenesis: VEGF, IGF‐1 secretion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0018"> <li> <p>Improve cognitive and motor function</p> </li> <li> <p>Inhibit neuronal apoptosis</p> </li> <li> <p>Stimulate blood vessel formation and reduce infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0059" title="GrandvuilleminI , GarrigueP , RamdaniA , BoubredF , SimeoniU , Dignat-GeorgeF , et al. Long-term recovery after endothelial colony-forming cells or human umbilical cord blood cells administration in a rat model of neonatal hypoxic-ischemic encephalopathy. Stem Cells Translational Medicine2017;6(11):1987-96. [PMID: 28980775]">Grandvuillemin 2017</a>; <a href="./references#CD013202-bbs2-0078" title="KidaniY , MikiY , NomimuraN , MinakawaS , TanakaN , MiyoshiH , et al. The therapeutic effect of CD133(+) cells derived from human umbilical cord blood on neonatal mouse hypoxic-ischemic encephalopathy model. Life Sciences2016;157:108-15. [PMID: 27287679]">Kidani 2016</a>; <a href="./references#CD013202-bbs2-0089" title="McDonaldCA , PennyTR , PatonMC , SutherlandAE , NekkantiL , YawnoT , et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. Journal of Neuroinflammation2018;15(1):47. [PMID: 29454374]">McDonald 2018</a>; <a href="./references#CD013202-bbs2-0096" title="NabetaniM , ShintakuH , HamazakiT . Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2018;83(1-2):356-63. [PMID: 29016557]">Nabetani 2018</a>; <a href="./references#CD013202-bbs2-0151" title="WangJ , ChenY , YangY , XiaoX , ChenS , ZhangC , et al. Endothelial progenitor cells and neural progenitor cells synergistically protect cerebral endothelial cells from Hypoxia/reoxygenation-induced injury via activating the PI3K/Akt pathway. Molecular Brain2016;9:12. [PMID: 26842559]">Wang 2016</a>; <a href="./references#CD013202-bbs2-0155" title="WuCC , ChenYC , ChangYC , WangLW , LinYC , ChiangYL , et al. Human umbilical vein endothelial cells protect against hypoxic-ischemic damage in neonatal brain via stromal cell-derived factor 1/C-X-C chemokine receptor type 4. Stroke2013;44(5):1402-9. [PMID: 23449265]">Wu 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin fibroblasts, umbilical cord tissue, amniotic tissue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0019"> <li> <p>Autologous administration</p> </li> <li> <p>Differentiation into multiple neural lineage cells</p> </li> <li> <p>Low immunogenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0020"> <li> <p>Differentiate into functional neural cells (electrophysiological properties)</p> </li> <li> <p>Decrease infiltration of MPO+ neutrophils and CD11b+ microglia</p> </li> <li> <p>VEGF expression and organelle transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0021"> <li> <p>Improve survival and sensorimotor function</p> </li> <li> <p>Establish axonal connections</p> </li> <li> <p>Inhibit inflammation, neural apoptosis, and glial scar formation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0032" title="CaiJ , LiW , SuH , QinD , YangJ , ZhuF , et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. Journal of Biological Chemistry2010;285(15):11227-34.">Cai 2010</a>; <a href="./references#CD013202-bbs2-0069" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013202-bbs2-0103" title="OkiK , TatarishviliJ , WoodJ , KochP , WattananitS , MineY , et al. Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells (Dayton, Ohio)2012;30(6):1120-33. [PMID: 22495829]">Oki 2012</a>; <a href="./references#CD013202-bbs2-0117" title="PluchinoS , Peruzzotti-JamettiL . Rewiring the ischaemic brain with human-induced pluripotent stem cell-derived cortical neurons. Brain2013;136(Pt 12):3525-7. [PMID: 24335051]">Pluchino 2013</a>; <a href="./references#CD013202-bbs2-0120" title="QinJ , MaX , QiH , SongB , WangY , WenX , et al. Transplantation of induced pluripotent stem cells alleviates cerebral inflammation and neural damage in hemorrhagic stroke. PloS One2015;10(6):e0129881. [PMID: 26086994]">Qin 2015</a>; <a href="./references#CD013202-bbs2-0140" title="TorneroD , WattananitS , Gronning MadsenM , KochP , WoodJ , TatarishviliJ , et al. Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery. Brain2013;136(Pt 12):3561-77. [PMID: 24148272]">Tornero 2013</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BDNF: brain‐derived neurotrophic factor; CNS: central nervous system; ESC: embryonic stem cell; EGF: epidermal growth factor; GDNF: glial cell‐line derived neurotrophic factor; HGF: hepatocyte growth factor; HLA: human leukocyte antigen; HSC: haematopoietic stem cells; IGF‐1: insulin‐like growth factor 1; iPSC: inducible pluripotent stem cells; IL: interleukin; MHC: major histocompatibility complex; MSC: mesenchymal stem cell; MNC: mononuclear cells; NF‐κB: nuclear factor kappa beta; NGF: nerve growth factor; NSC: neural stem cells; OPC: oligodendrocyte progenitor cells; RCT: randomised controlled trial; TNF: tumour necrosis factor; VEGF: vascular endothelial growth factor. </p> </div> </div> <section id="CD013202-sec-0012"> <h4 class="title">Mesenchymal stem cells</h4> <p>The beneficial effects of MSCs occur at the cellular and functional level. The proposed mechanism of action is through the paracrine release of factors known to improve neurogenesis, such as basic fibroblast growth factor, insulin‐like growth factor‐1, and anti‐inflammatory cytokines (<a href="./references#CD013202-bbs2-0083" title="LiY , ChenJ , ChenXG , WangL , GautamSC , XuYX , et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology2002;59(4):514-23. [PMID: 12196642]">Li 2002</a>; <a href="./references#CD013202-bbs2-0094" title="MurphyMB , MoncivaisK , CaplanAI . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental &amp; Molecular Medicine2013;45:e54. [DOI: 10.1038/emm.2013.94] [PMID: 24232253]">Murphy 2013</a>; <a href="./references#CD013202-bbs2-0121" title="QuR , LiY , GaoQ , ShenL , ZhangJ , LiuZ , et al. Neurotrophic and growth factor gene expression profiling of mouse bone marrow stromal cells induced by ischemic brain extracts. Neuropathology2007;27(4):355-63. [PMID: 17899689]">Qu 2007</a>; <a href="./references#CD013202-bbs2-0143" title="vanVelthovenCT , KavelaarsA , vanBelF , HeijnenCJ . Regeneration of the ischemic brain by engineered stem cells: fuelling endogenous repair processes. Brain Research Reviews2009;61(1):1-13. [10.1016/j.brainresrev.2009.03.003] [PMID: 19348860]">van Velthoven 2009</a>; <a href="./references#CD013202-bbs2-0144" title="vanVelthovenCT , KavelaarsA , vanBelF , HeijnenCJ . Mesenchymal stem cell transplantation changes the gene expression profile of the neonatal ischemic brain. Brain Behavioral Immunology2011;25(7):1342-8. [DOI: 10.1016/j.bbi.2011.03.021] [PMID: 21473911]">van Velthoven 2011</a>; <a href="./references#CD013202-bbs2-0145" title="vanVelthovenCT , KavelaarsA , HeijnenCJ . Mesenchymal stem cells as a treatment for neonatal ischemic brain damage. Pediatric Research2012;71(4 Pt 2):474-81. [DOI: 10.1038/pr.2011.64] [PMID: 22430383]">van Velthoven 2012</a>). MSCs can also modulate the local immune response by regulating the function of immune cells, such as T‐cells and B‐cells, macrophages, and dendritic cells (<a href="./references#CD013202-bbs2-0073" title="IyerSS , RojasM . Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opinion on Biological Therapy2008;8(5):569-81. [DOI: 10.1517/14712598.8.5.569] [PMID: 18407762]">Iyer 2008</a>). Furthermore, in injured brain tissue MSCs upregulate the expression of genes associated with cell proliferation (e.g. Spp1 and interleukin (IL) 17 (IL‐17)), neurogenesis (neural cell adhesion molecule and nerve growth factor), migration (CXCR4), neuronal survival (glial‐derived neurotrophic factor), and down regulation of genes involved in inflammation (i.e. IL‐1β) (<a href="./references#CD013202-bbs2-0144" title="vanVelthovenCT , KavelaarsA , vanBelF , HeijnenCJ . Mesenchymal stem cell transplantation changes the gene expression profile of the neonatal ischemic brain. Brain Behavioral Immunology2011;25(7):1342-8. [DOI: 10.1016/j.bbi.2011.03.021] [PMID: 21473911]">van Velthoven 2011</a>). In addition, MSCs may inhibit apoptosis by transporting mitochondria through tunnelling nanotubules in efforts to rescue aerobic respiration (<a href="./references#CD013202-bbs2-0086" title="LiuK , JiK , GuoL , WuW , LuH , ShanP , et al. Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia-reperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer. Microvascular Research2014;92:10-8. [DOI: 10.1016/j.mvr.2014.01.008] [PMID: 24486322]">Liu 2014</a>). </p> <p>At the functional level, MSC treatment, given within the first 10 days after injury, prevents neuroinflammation and apoptosis (<a href="./references#CD013202-bbs2-0030" title="BonestrooHJ , HeijnenCJ , GroenendaalF , vanBelF , NijboerCH . Development of cerebral gray and white matter injury and cerebral inflammation over time after inflammatory perinatal asphyxia. Developmental Neuroscience2015;37(1):78-94. [DOI: 10.1159/000368770] [PMID: 25634435]">Bonestroo 2015</a>; <a href="./references#CD013202-bbs2-0044" title="DonegaV , vanVelthovenCT , NijboerCH , vanBelF , KasMJ , KavelaarsA , et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PloS One2013;8(1):e51253. [DOI: 10.1371/journal.pone.0051253] [PMID: 23300948]">Donega 2013</a>). The administration of umbilical‐cord‐derived MSCs resulted in nerve fibre remyelination and axonal regeneration, diminished loss of white and grey matter, improved sensorimotor function, and promoted better long‐term neurological recovery (<a href="./references#CD013202-bbs2-0044" title="DonegaV , vanVelthovenCT , NijboerCH , vanBelF , KasMJ , KavelaarsA , et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. PloS One2013;8(1):e51253. [DOI: 10.1371/journal.pone.0051253] [PMID: 23300948]">Donega 2013</a>; <a href="./references#CD013202-bbs2-0045" title="DonegaV , NijboerCH , vanVelthovenCT , YoussefSA , deBruinA , vanBelF , et al. Assessment of long-term safety and efficacy of intranasal mesenchymal stem cell treatment for neonatal brain injury in the mouse. Pediatric Research2015;78(5):520-6. [DOI: 10.1038/pr.2015.145] [PMID: 26270577]">Donega 2015</a>; <a href="./references#CD013202-bbs2-0085" title="LiuAM , LuG , TsangKS , LiG , WuY , HuangZS , et al. Umbilical cord-derived mesenchymal stem cells with forced expression of hepatocyte growth factor enhance remyelination and functional recovery in a rat intracerebral hemorrhage model. Neurosurgery2010;67(2):357-65; discussion 365-6. [DOI: 10.1227/01.NEU.0000371983.06278.B3] [PMID: 20644422]">Liu 2010</a>; <a href="./references#CD013202-bbs2-0093" title="MoránJ , StokowskaA , WalkerFR , MallardC , HagbergH , PeknaM . Intranasal C3a treatment ameliorates cognitive impairment in a mouse model of neonatal hypoxic-ischemic brain injury. Experimental Neurology2017;290:74-84. [DOI: 10.1016/j.expneurol.2017.01.001] [PMID: 28062175]">Morán 2017</a>). </p> </section> <section id="CD013202-sec-0013"> <h4 class="title">Mononuclear cells</h4> <p>In a newborn lamb model of HIE, treatment with mononuclear cells obtained from umbilical cord blood promoted a decrease in neuronal apoptosis and inflammation, along with a trend towards a reduction in seizures (<a href="./references#CD013202-bbs2-0023" title="AridasJD , McDonaldCA , PatonMC , YawnoT , SutherlandAE , NitsosI , et al. Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb. Journal of Physiology2016;594(5):1421-35. [DOI: 10.1113/JP271104] [PMID: 26527561]">Aridas 2016</a>). Mononuclear cells also reduce motor deficits and cortical brain loss by decreasing CD4+ T‐cell and microglial infiltration to the injury site (<a href="./references#CD013202-bbs2-0089" title="McDonaldCA , PennyTR , PatonMC , SutherlandAE , NekkantiL , YawnoT , et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. Journal of Neuroinflammation2018;15(1):47. [PMID: 29454374]">McDonald 2018</a>). </p> </section> <section id="CD013202-sec-0014"> <h4 class="title">Oligodendrocyte progenitor cells</h4> <p>Administration of oligodendrocyte progenitor cells to a small animal model of cervical spinal injury increased myelination and enhanced motor performance (<a href="./references#CD013202-bbs2-0088" title="ManleyNC , PriestCA , DenhamJ , Wirth ED 3rd, LebkowskiJS . Human embryonic stem cell-derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Translational Medicine2017;6(10):1917-29. [PMID: 28834391]">Manley 2017</a>). Differentiation into myelin‐producing cells and expression of brain‐derived neurotrophic factor and bcl‐2 appear to be mechanisms by which oligodendrocyte progenitor cells encourage learning and memory in neonatal asphyxia (<a href="./references#CD013202-bbs2-0034" title="ChenLX , MaSM , ZhangP , FanZC , XiongM , ChengGQ , et al. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury. PloS One2015;10(3):e0115997.">Chen 2015</a>). </p> </section> <section id="CD013202-sec-0015"> <h4 class="title">Neural stem cells</h4> <p>Mine and colleagues showed that intrastriatal transplantation of neural stem cells slows inflammation (microglia/macrophage activation) and promotes axonal connections (<a href="./references#CD013202-bbs2-0090" title="MineY , TatarishviliJ , OkiK , MonniE , KokaiaZ , LindvallO . Grafted human neural stem cells enhance several steps of endogenous neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiology of Disease2013;52:191-203. [PMID: 23276704]">Mine 2013</a>). Moreover, it is posited that neural stem cell therapy inhibits IL‐1β expression and improves neural plasticity by upregulating nuclear factor kappa β signalling (<a href="./references#CD013202-bbs2-0075" title="JiG , LiuM , ZhaoXF , LiuXY , GuoQL , GuanZF , et al. NF-kappaB signaling is involved in the effects of intranasally engrafted human neural stem cells on neurofunctional improvements in neonatal rat hypoxic-ischemic encephalopathy. CNS Neuroscience &amp; Therapeutics2015;21(12):926-35. [PMID: 26255634]">Ji 2015</a>). </p> </section> <section id="CD013202-sec-0016"> <h4 class="title">Haematopoietic stem cells</h4> <p>Human umbilical cord 34+ cells given 48 hours after middle cerebral artery occlusion in mice transiently increased cerebral blood flow and blood vessel diameter in the peri‐infarct area (<a href="./references#CD013202-bbs2-0142" title="TsujiM , TaguchiA , OhshimaM , KasaharaY , SatoY , TsudaH , et al. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience2014;263:148-58. [PMID: 24444827]">Tsuji 2014</a>). These findings can be attributed to the release of growth factors (i.e. vascular endothelial growth factor and glial‐derived neurotrophic factor) known to stimulate neurogenesis and angiogenesis (<a href="./references#CD013202-bbs2-0146" title="VerinaT , FatemiA , JohnstonMV , ComiAM . Pluripotent possibilities: human umbilical cord blood cell treatment after neonatal brain injury. Pediatric Neurology2013;48(5):346-54. [PMID: 23583051]">Verina 2013</a>). </p> </section> <section id="CD013202-sec-0017"> <h4 class="title">Endothelial cells</h4> <p>The neuroprotective effects of endothelial cells are ascribed to their ability in decreasing neuroinflammation and cell apoptosis (<a href="./references#CD013202-bbs2-0059" title="GrandvuilleminI , GarrigueP , RamdaniA , BoubredF , SimeoniU , Dignat-GeorgeF , et al. Long-term recovery after endothelial colony-forming cells or human umbilical cord blood cells administration in a rat model of neonatal hypoxic-ischemic encephalopathy. Stem Cells Translational Medicine2017;6(11):1987-96. [PMID: 28980775]">Grandvuillemin 2017</a>). Intraperitoneal injection of human umbilical vein endothelial cells preserved microvessels and lessened apoptosis in the cortex of treated animals, via regulation of stromal cell‐derived factor 1 and CXC chemokine receptor 4 (<a href="./references#CD013202-bbs2-0155" title="WuCC , ChenYC , ChangYC , WangLW , LinYC , ChiangYL , et al. Human umbilical vein endothelial cells protect against hypoxic-ischemic damage in neonatal brain via stromal cell-derived factor 1/C-X-C chemokine receptor type 4. Stroke2013;44(5):1402-9. [PMID: 23449265]">Wu 2013</a>). </p> </section> <section id="CD013202-sec-0018"> <h4 class="title">Inducible pluripotent stem cells</h4> <p>Using human‐skin‐derived inducible pluripotent stem cells, Tornero and colleagues produced cortical progenitor cells that survived and differentiated into functional neurons that improved performance of impaired limb movement in a rat stroke model (<a href="./references#CD013202-bbs2-0140" title="TorneroD , WattananitS , Gronning MadsenM , KochP , WoodJ , TatarishviliJ , et al. Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery. Brain2013;136(Pt 12):3561-77. [PMID: 24148272]">Tornero 2013</a>). Furthermore, inducible pluripotent stem cell treatment reduced the number of inflammatory cells and glial scar formation in a preclinical study of haemorrhagic stroke (<a href="./references#CD013202-bbs2-0120" title="QinJ , MaX , QiH , SongB , WangY , WenX , et al. Transplantation of induced pluripotent stem cells alleviates cerebral inflammation and neural damage in hemorrhagic stroke. PloS One2015;10(6):e0129881. [PMID: 26086994]">Qin 2015</a>). </p> <p>Taken together, regenerative cells may exert their therapeutic benefit through multiple routes to establish a favourable environment for tissue regeneration, which ultimately leads to better functional outcomes following hypoxic‐ischaemic damage. </p> </section> </section> <section id="CD013202-sec-0019"> <h3 class="title" id="CD013202-sec-0019">Why it is important to do this review</h3> <p>It is important to conduct this review as regenerative cells might be an effective intervention for the prevention and treatment of HIE, which is one of the most severe morbidities in term infants. To date, US clinical trials studying the safety, feasibility, efficacy (or a combination of these) of regenerative cells have been registered for bronchopulmonary dysplasia, HIE, hypoplastic left heart syndrome, and intraventricular haemorrhage. The most widespread tissue used to derive regenerative cells is the umbilical cord (<a href="./references#CD013202-bbs2-0091" title="MitsialisSA , KourembanasS . Stem cell-based therapies for the newborn lung and brain: possibilities and challenges. Seminars in Perinatology2016;40(3):138-51.">Mitsialis 2016</a>; <a href="./references#CD013202-bbs2-0158" title="YoonS , YunA , ChangS , ParkWS . Stem cells for neonatal brain disorders. Neonatology2016;109(4):377-83.">Yoon 2016</a>). While MSCs dominate as cell type, a few trials are evaluating neural progenitor cells, mononuclear cells, and placenta/cord blood cells (<a href="./references#CD013202-bbs2-0014" title="NCT02434965. Autologous cord blood and human placental derived stem cells in neonates with severe hypoxic-ischemic encephalopathy (HPDSC+HIE). clinicaltrials.gov/ct2/show/record/NCT02434965?term=NCT02434965&amp;rank=1 (first received 6 May 2015). ">NCT02434965</a>; <a href="./references#CD013202-bbs2-0017" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579?term=NCT02854579&amp;rank=1 (first received 3 August 2016). Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy (HIE). apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02854579 (first received 23 November 2015). ">NCT02854579</a>; <a href="./references#CD013202-bbs2-0100" title="NCT02999373. Prevention of preterm infection by autologous umbilical cord blood mononuclear cells therapy [Autologous cord blood mononuclear cells for bronchopulmonary dysplasia in very preterm neonates]. clinicaltrials.gov/ct2/show/NCT02999373 (first received 21 December 2016).">NCT02999373</a>). </p> <p>The efficacy and safety of use of regenerative cell administration has been assessed in several systematic reviews and meta‐analyses. For instance, the safety of MSCs has been evaluated in a meta‐analysis across different disciplines (eight studies including 321 adults): there was no association between acute infusional toxicity, organ system complications, infection, death or malignancy (<a href="./references#CD013202-bbs2-0081" title="LaluMM , McIntyreL , PuglieseC , FergussonD , WinstonBW , MarshallJC , et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PloS One2012;7(10):e47559. [DOI: 10.1371/journal.pone.0047559] [PMID: 23133515]">Lalu 2012</a>). However, the risk of potential tumourigenicity related to MSC‐based interventions needs to be further elucidated (<a href="./references#CD013202-bbs2-0024" title="BarkholtL , FloryE , JekerleV , Lucas-SamuelS , AhnertP , BissetL , et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies – bridging scientific observations and regulatory viewpoints. Cytotherapy2013;15(7):753-9. [DOI: 10.1016/j.jcyt.2013.03.005] [PMID: 23602595]">Barkholt 2013</a>). The Cochrane Review 'Stem cell transplantation for ischaemic stroke' included three small trials in adults (<a href="./references#CD013202-bbs2-0029" title="BoncoraglioGB , BersanoA , CandeliseL , ReynoldsBA , ParatiEA . Stem cell transplantation for ischemic stroke. Cochrane Database of Systematic Reviews2010, Issue 9. Art. No: CD007231. [DOI: 10.1002/14651858.CD007231.pub2]">Boncoraglio 2010</a>). In newborns, one Cochrane Review has been conducted on MSC for the prevention and treatment of bronchopulmonary dysplasia in preterm infants (<a href="./references#CD013202-bbs2-0115" title="PierroM , ThebaudB , SollR . Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011932. [DOI: 10.1002/14651858.CD011932.pub2] [PMID: 29125893]">Pierro 2017</a>). Early phase trials have been conducted (or are underway) on the use of MSCs or cord blood cells (or both) for bronchopulmonary dysplasia, severe IVH (<a href="./references#CD013202-bbs2-0099" title="NCT02274428. Phase 1 clinical trial of PNEUMOSTEM® treatment in premature infants with intraventricular hemorrhage. clinicaltrials.gov/ct2/show/NCT02274428 (first received 2 October 2014).">NCT02274428</a>), and HIE (<a href="./references#CD013202-bbs2-0033" title="ChangYS , AhnSY , YooHS , SungSI , ChoiSJ , OhWI , et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. Journal of Pediatrics2014;164(5):966-72.e6. [DOI: 10.1016/j.jpeds.2013.12.011] [ClinicalTrials.gov NCT01297205] [PMID: 24508444]">Chang 2014</a>; <a href="./references#CD013202-bbs2-0001" title="CottenCM ,  MurthaAP ,  GoldbergRN ,  GrotegutCA ,  SmithPB ,  GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013202-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013202-sec-0020"></div> <p>To determine the efficacy and safety of stem cell‐based interventions for the treatment of hypoxic‐ischaemic encephalopathy (HIE) in newborn infants. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013202-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013202-sec-0021"></div> <section id="CD013202-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013202-sec-0023"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), quasi‐RCTs, and cluster trials.</p> </section> <section id="CD013202-sec-0024"> <h4 class="title">Types of participants</h4> <p> <ul id="CD013202-list-0022"> <li> <p>Term infants (37 weeks or greater) and late preterm infants (34+0 to 36+6 weeks' gestation) 10 days of age or less. </p> </li> <li> <p>Evidence of peripartum asphyxia, characterized by evidence of neonatal or foetal distress with each enrolled infant satisfying at least one of the following criteria. </p> <ul id="CD013202-list-0023"> <li> <p>Cord gas or postnatal blood gas (within the first hour of life) with pH 7.0 or less or base deficit 12 mEq/L or greater. </p> </li> <li> <p>Apgar score 5 or less at five minutes.</p> </li> <li> <p>Need for mechanical ventilation or resuscitation at 10 minutes of life.</p> </li> <li> <p>With or without evidence of encephalopathy (moderate or severe) according to Sarnat staging (<a href="./references#CD013202-bbs2-0129" title="SarnatHB , SarnatMS . Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Archives of Neurology1976;33(10):696-705. [PMID: 987769]">Sarnat 1976</a>): </p> <ul id="CD013202-list-0024"> <li> <p>Stage 1 (mild): hyperalertness, hyper‐reflexia, dilated pupils, tachycardia, absence of seizures; </p> </li> <li> <p>Stage 2 (moderate): lethargy, hyper‐reflexia, miosis, bradycardia, seizures, hypotonia with weak suck and Moro reflex; </p> </li> <li> <p>Stage 3 (severe): stupor, flaccidity, small‐to‐mid position pupils that react poorly to light, decreased stretch reflexes, hypothermia, and absent Moro reflex. </p> </li> </ul> </li> </ul> </li> <li> <p>No major congenital abnormalities recognizable at birth.</p> </li> </ul> </p> </section> <section id="CD013202-sec-0025"> <h4 class="title">Types of interventions</h4> <section id="CD013202-sec-0026"> <h5 class="title">Comparison 1</h5> <p>Stem cell‐based interventions (any type) compared to control (placebo or no treatment).</p> </section> <section id="CD013202-sec-0027"> <h5 class="title">Comparison 2</h5> <p>Use of MSCs of type (e.g. number of doses or passages) or source (e.g. autologous versus allogeneic, or bone marrow versus cord) versus MSCs of other type or source. </p> </section> <section id="CD013202-sec-0028"> <h5 class="title">Comparison 3</h5> <p>Use of stem cell‐based interventions other than MSCs of type (e.g. mononuclear cells, oligodendrocyte progenitor cells, neural stem cells, haematopoietic stem cells, and inducible pluripotent stem cells) or source (e.g. autologous versus allogeneic, or bone marrow versus cord) versus stem cell‐based interventions other than MSCs of other type or source. </p> </section> <section id="CD013202-sec-0029"> <h5 class="title">Comparison 4</h5> <p>MSCs versus stem cell‐based interventions other than MSCs.</p> <p>We included all types of transplantation regardless of cell source (bone marrow, cord blood versus Wharton's jelly, placenta, adipose tissue, peripheral blood), type of graft (autologous or allogeneic), and dose. We excluded stem cell‐derived cerebral organoids (<a href="./references#CD013202-bbs2-0041" title="Di LulloE , KriegsteinAR . The use of brain organoids to investigate neural development and disease. Nature Reviews. Neuroscience2017;18(10):573-84. [PMID: 28878372]">Di Lullo 2017</a>). </p> <p>Characteristic of the interventions and co‐interventions (e.g. cooling) are specified in <a href="#CD013202-sec-0046">Subgroup analysis and investigation of heterogeneity</a>. </p> </section> </section> <section id="CD013202-sec-0030"> <h4 class="title">Types of outcome measures</h4> <section id="CD013202-sec-0031"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013202-list-0025"> <li> <p>All‐cause neonatal mortality (mortality less than 28 days of age).</p> </li> <li> <p>Major neurodevelopmental disability: cerebral palsy, developmental delay (Bayley Mental Developmental Index or Griffiths Mental Development Scale assessment greater than two standard deviations (SD) below the mean) (<a href="./references#CD013202-bbs2-0026" title="BayleyN . Bayley Scales of Infant Development. 2nd edition. San Antonio (TX): The Psychological Corporation, 1993.">Bayley 1993</a>; <a href="./references#CD013202-bbs2-0027" title="BayleyN . Bayley Scales of Infant and Toddler Development. San Antonio (TX): Harcourt Assessment, 2006.">Bayley 2006</a>; <a href="./references#CD013202-bbs2-0061" title="GriffithsR . The Abilities of Babies: a Study in Mental Measurement. New York (NY): McGraw-Hill Book Co. Inc, 1954.">Griffiths 1954</a>); intellectual impairment (intelligence quotient (IQ) greater than two SDs below the mean); blindness (vision less than 6/60 in both eyes); or sensorineural deafness requiring amplification (<a href="./references#CD013202-bbs2-0074" title="JacobsSE , BergM , HuntR , Tarnow-MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD003311. [DOI: 10.1002/14651858.CD003311.pub3]">Jacobs 2013</a>). We planned to separately assess data on children aged 18 to 24 months and aged three to five years. </p> </li> <li> <p>Death or major neurodevelopmental disability assessed at 18 to 24 months of age (defined as cerebral palsy, developmental delay (Bayley or Griffith assessment more than two SD below the mean) or intellectual impairment (IQ more than two SD below mean); blindness (vision less than 6/60 in both eyes); or sensorineural deafness requiring amplification) (<a href="./references#CD013202-bbs2-0026" title="BayleyN . Bayley Scales of Infant Development. 2nd edition. San Antonio (TX): The Psychological Corporation, 1993.">Bayley 1993</a>; <a href="./references#CD013202-bbs2-0027" title="BayleyN . Bayley Scales of Infant and Toddler Development. San Antonio (TX): Harcourt Assessment, 2006.">Bayley 2006</a>; <a href="./references#CD013202-bbs2-0061" title="GriffithsR . The Abilities of Babies: a Study in Mental Measurement. New York (NY): McGraw-Hill Book Co. Inc, 1954.">Griffiths 1954</a>; <a href="./references#CD013202-bbs2-0074" title="JacobsSE , BergM , HuntR , Tarnow-MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD003311. [DOI: 10.1002/14651858.CD003311.pub3]">Jacobs 2013</a>). </p> </li> </ul> </p> </section> <section id="CD013202-sec-0032"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013202-list-0026"> <li> <p>All‐cause mortality prior to first hospital discharge</p> </li> <li> <p>Each component of major neurodevelopmental disability (we planned to report these components of long‐term outcome for all studies that have evaluated children after 18 months' chronological age; we planned to perform separate analyses for children aged 18 to 24 months and three to five years). </p> <ul id="CD013202-list-0027"> <li> <p>Cerebral palsy</p> </li> <li> <p>Developmental delay</p> <ul id="CD013202-list-0028"> <li> <p>Bayley or Griffith assessment more than two SD below the mean</p> </li> <li> <p>Neuromotor development (Bayley Scales of Infant Development – Psychomotor Development Index (BSID PDI)) assessed in survivors </p> </li> <li> <p>Cognitive development (Bayley Scales of Infant Development – Mental Development Index (BSID MDI)) assessed in survivors </p> </li> </ul> </li> <li> <p>Intellectual impairment (IQ more than two SD below mean)</p> </li> <li> <p>Blindness (vision less than 6/60 in both eyes)</p> </li> <li> <p>Sensorineural deafness requiring amplification</p> </li> </ul> </li> <li> <p>Seizures (suspected clinically or identified by electroencephalogram (EEG) or amplitude‐integrated electroencephalogram (aEEG)) </p> <ul id="CD013202-list-0029"> <li> <p>Seizures during neonatal period (after MSC administration)</p> </li> <li> <p>Seizures or need for anticonvulsants at follow‐up 12 to 14 months of age</p> </li> </ul> </li> <li> <p>Cystic periventricular leukomalacia on brain ultrasound in the first month of life</p> </li> <li> <p>Brain magnetic resonance imaging (MRI) abnormalities (yes/no), defined as white matter lesions (i.e. cavitations; <a href="./references#CD013202-bbs2-0127" title="RutherfordMA , SupramaniamV , EderiesA , ChewA , BassiL , GroppoM , et al. Magnetic resonance imaging of white matter diseases of prematurity. Neuroradiology2010;52(6):505-21. [DOI: 10.1007/s00234-010-0700-y] [PMID: 20422407]">Rutherford 2010</a>) and punctate lesions (<a href="./references#CD013202-bbs2-0037" title="CornetteLG , TannerSF , RamenghiLA , MiallLS , ChildsAM , ArthurRJ , et al. Magnetic resonance imaging of the infant brain: anatomical characteristics and clinical significance of punctate lesions. Archives of Disease in Childhood. Fetal and Neonatal Edition2002;86(3):F171-7. [PMID: 11978747]">Cornette 2002</a>); germinal matrix‐intraventricular haemorrhage (GM‐IVH) (<a href="./references#CD013202-bbs2-0108" title="ParodiA , MoranaG , SeverinoMS , MalovaM , NataliziaAR , SanniaA , et al. Low-grade intraventricular hemorrhage: is ultrasound good enough?Journal of Maternal-fetal &amp; Neonatal Medicine2015;28(Suppl 1):2261-4. [DOI: 10.3109/14767058.2013.796162] [PMID: 23968243]">Parodi 2015</a>); or cerebellar haemorrhage (<a href="./references#CD013202-bbs2-0084" title="LimperopoulosC , BassanH , GauvreauK , Robertson RL Jr, SullivanNR , BensonCB , et al. Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors?Pediatrics2007;120(3):584-93. [DOI: 10.1542/peds.2007-1041] [PMID: 17766532]">Limperopoulos 2007</a>) </p> </li> <li> <p>Duration of hospital stay (days)</p> </li> <li> <p>Tumour formation, any type, any location, detected by MRI or computed tomography (to assess the risk of tumourigenicity of donor MSCs) </p> </li> <li> <p>Immune‐rejection or any serious adverse event (certain, probable or possible according to the World Health Organization (WHO) probability scale). We planned to consider post hoc analyses for any unexpected adverse effects reported by the studies. </p> </li> </ul> </p> </section> </section> </section> <section id="CD013202-sec-0033"> <h3 class="title">Search methods for identification of studies</h3> <p>We used the criteria and standard methods of Cochrane and Cochrane Neonatal (see <a href="http://neonatal.cochrane.org/resources-review-authors" target="_blank">the Cochrane Neonatal search strategy for specialized register</a>). We searched for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) and report the date this was done within the review. </p> <section id="CD013202-sec-0034"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive search including: Cochrane Central Register of Controlled Trials (CENTRAL, 2020 Issue 5) in the Cochrane Library; MEDLINE via PubMed (1996 to 8 June 2020); Embase (1980 to 8 June 2020); and CINAHL (1982 to 8 June 2020). Please see <a href="./appendices#CD013202-sec-0070">Appendix 1</a> for the full search strategies for each database. We applied no language restrictions. We searched clinical trials registries for ongoing or recently completed trials (<a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>; the WHO's International <a href="http://www.whoint/ictrp/search/en/" target="_blank">Trials Registry and Platform</a>; and the <a href="http://www.isrctn.com/" target="_blank">ISRCTN Registry</a>; see <a href="./appendices#CD013202-sec-0070">Appendix 1</a>). </p> </section> <section id="CD013202-sec-0035"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of all identified articles for relevant articles not identified in the primary search. </p> </section> </section> <section id="CD013202-sec-0036"> <h3 class="title" id="CD013202-sec-0036">Data collection and analysis</h3> <p>We used the standard methods of Cochrane Neonatal, as described below.</p> <section id="CD013202-sec-0037"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MB, OR) independently searched for and identified eligible trials that met the inclusion criteria. We screened the titles and abstracts to identify potentially relevant citations, and retrieved the full texts of all potentially relevant articles; and we independently assessed the eligibility of studies by filling out eligibility forms designed in accordance with the specified inclusion criteria. We excluded studies published only in abstract form unless the final results of the trial were reported and all necessary information can be ascertained from the abstract or authors, or both. We reviewed studies for relevance by assessing study design, types of participants, interventions provided, and outcome measures reported. We resolved disagreements by discussion and, if necessary, by consultation with a third review author (DL). We provide details of excluded studies in the <a href="./references#CD013202-sec-0081" title="">Characteristics of excluded studies</a> table, along with reasons for exclusion. We contacted trial authors if details of primary trials were unclear. </p> </section> <section id="CD013202-sec-0038"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MB, OR) independently extracted data using a data extraction form integrated with a modified version of the Cochrane Effective Practice and Organisation of Care Group data collection checklist (<a href="./references#CD013202-bbs2-0036" title="Cochrane Effective Practice and Organisation of Care (EPOC). Screening, data extraction and management. EPOC Resources for Review Authors, 2017. epoc.cochrane.org/epoc-specific-resources-review-authors (accessed prior to 20 September 2018).">Cochrane EPOC Group 2017</a>). </p> <p>We planned to extract the following characteristics from each included study.</p> <p> <ul id="CD013202-list-0030"> <li> <p>Administrative details: study author(s); published or unpublished; year of publication; year in which study was conducted; presence of vested interest; details of other relevant papers cited. </p> </li> <li> <p>Details of the study: study design; type, duration, and completeness of follow‐up (e.g. greater than 80%); country and location of study; informed consent; ethics approval. </p> </li> <li> <p>Details of participants: sex, birth weight, gestational age, number of participants.</p> </li> <li> <p>Details of interventions: initiation, dose, and duration of MSCs' administration; co‐intervention such as cooling. </p> </li> <li> <p>Details of outcomes as mentioned above under <a href="#CD013202-sec-0030">Types of outcome measures</a>. </p> </li> </ul> </p> <p>We resolved disagreements by discussion. We described ongoing studies identified by our search, when available, detailing the primary author, research question(s), methods, and outcome measures, together with an estimate of the reporting date. </p> <p>Should any queries have arisen or we required additional data, we planned to contact study investigators/authors for clarification. Two review authors (MB, OR) used <a href="./references#CD013202-bbs2-0122" title="The Cochrane CollaborationReview Manager Web (RevMan Web). The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web</a> for data entry. We planned to replace any standard error of the mean (SEM) by the corresponding SD. </p> </section> <section id="CD013202-sec-0039"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We planned to independently assess (OR, MB) the risk of bias (low, high, or unclear) of all included trials using the Cochrane ‘Risk of bias’ tool for the following domains (<a href="./references#CD013202-bbs2-0067" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook (accessed prior to 20 September 2018).">Higgins 2019</a>). </p> <p> <ul id="CD013202-list-0031"> <li> <p>Sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Any other bias.</p> </li> </ul> </p> <p>We planned to resolve any disagreements by discussion or by consultation with a third review author (AM). See <a href="./appendices#CD013202-sec-0072">Appendix 2</a> for a more detailed description of risk of bias for each domain. </p> </section> <section id="CD013202-sec-0040"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to use risk ratios (RRs), risk differences (RDs), numbers needed to treat for an additional beneficial outcome (NNTB) or numbers needed to treat for an additional harmful outcome (NNTH) for categorical variables, and mean differences (MDs) for continuous variables. We planned to replace any within‐group SEM reported in a trial by its corresponding SD using the formula SD = SEM × √n, where n is the number of participants. We planned to report 95% confidence intervals (CIs) for each statistic. </p> </section> <section id="CD013202-sec-0041"> <h4 class="title">Unit of analysis issues</h4> <p>We  planned to include all RCTs and quasi‐RCTs in which the unit of allocation was the individual infant. Should we have found any cluster‐RCTs, we would have adjusted analysis for the designed effect using the method stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013202-bbs2-0067" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook (accessed prior to 20 September 2018).">Higgins 2019</a>). </p> </section> <section id="CD013202-sec-0042"> <h4 class="title">Dealing with missing data</h4> <p>We planned to obtain a dropout rate for each study. If we found a significant dropout rate (e.g. greater than 20%), we would have contacted study author(s) to request additional data. We planned to perform a sensitivity analysis to evaluate the overall results with and without inclusion of studies with a significant dropout rate. If a study reported outcomes only for participants completing the trial or only for participants who followed the protocol, we would contact study author(s) to ask them to provide additional information to facilitate an intention‐to‐treat analysis; in instances when this was not possible, we planned to perform a complete‐case analysis. </p> </section> <section id="CD013202-sec-0043"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess clinical heterogeneity by comparing the distribution of important participant factors between trials and trial factors (randomisation concealment, blinding of outcome assessment, loss to follow‐up, treatment type, co‐interventions). We planned to assess statistical heterogeneity by examining the I² statistic (<a href="./references#CD013202-bbs2-0067" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook (accessed prior to 20 September 2018).">Higgins 2019</a>), a quantity that describes the proportion of variation in point estimates that is due to variability across studies rather than to sampling error. </p> <p>We planned to interpret the I² statistic as follows, as described by <a href="./references#CD013202-bbs2-0066" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [PMID: 12958120]">Higgins 2003</a>. </p> <p> <ul id="CD013202-list-0032"> <li> <p>Less than 25%: no heterogeneity.</p> </li> <li> <p>25% to 49%: low heterogeneity.</p> </li> <li> <p>50% to 74%: moderate heterogeneity.</p> </li> <li> <p>75% or greater: high heterogeneity.</p> </li> </ul> </p> <p>We planned to consider statistical heterogeneity to be substantial when the I² statistic was 50% or greater. In addition, we planned to employ the Chi² test of homogeneity to determine the strength of evidence that heterogeneity is genuine. We planned to explore clinical variation across studies by comparing the distribution of important participant factors among trials and trial factors (randomisation concealment, blinding of outcome assessment, loss to follow‐up, treatment types, and co‐interventions). We planned to consider a threshold of P value less than 0.1 as an indicator of whether heterogeneity (genuine variation in effect sizes) was present. </p> </section> <section id="CD013202-sec-0044"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to examine the possibility of within‐study selective outcome reporting for each study included in the review. We planned to search for trial protocols of included trials on electronic sources such as PubMed, ClinicalTrials.gov, and the WHO ICTRP to assess whether outcome reporting seemed to be sufficiently complete and transparent. We planned to investigate publication bias by using funnel plots if we included 10 or more clinical trials in the systematic review (<a href="./references#CD013202-bbs2-0047" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMID: 9310563]">Egger 1997</a>; <a href="./references#CD013202-bbs2-0067" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook (accessed prior to 20 September 2018).">Higgins 2019</a>). </p> </section> <section id="CD013202-sec-0045"> <h4 class="title">Data synthesis</h4> <p>We planned to perform statistical analyses according to the recommendations of Cochrane Neonatal (<a href="http://neonatal.cochrane.org/en/index.html" target="_blank">neonatal.cochrane.org/en/index.html</a>) using <a href="./references#CD013202-bbs2-0122" title="The Cochrane CollaborationReview Manager Web (RevMan Web). The Cochrane Collaboration, 2019. Available at revman.cochrane.org.">RevMan Web</a>. We planned to analyse all infants randomised on an intention‐to‐treat basis. We planned to analyse treatment effects in the individual trials. We planned to use a fixed‐effect model to combine the data. For any meta‐analyses, we would have synthesized data using RR, RD, NNTB, NNTH, MD, and 95% CI. We planned to analyse and interpret individual trials separately when we judged meta‐analysis to be inappropriate. </p> </section> <section id="CD013202-sec-0046"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses.</p> <p>For MSCs trials:</p> <p> <ul id="CD013202-list-0033"> <li> <p>gestational age: term infants (≥ 37 weeks' gestation), late preterm infants (34 to 36+6 weeks' gestation); </p> </li> <li> <p>HIE severity stage: mild, moderate, and severe (Sarnat);</p> </li> <li> <p>chronological age: less than three days, three days or greater;</p> </li> <li> <p>co‐intervention: with/without cooling;</p> </li> <li> <p>MSCs source: bone marrow, cord blood versus Wharton's jelly, placenta, adipose tissue, peripheral blood; </p> </li> <li> <p>type of graft: autologous or allogeneic;</p> </li> <li> <p>preconditioned (yes, no);</p> </li> <li> <p>fresh or frozen and thawed;</p> </li> <li> <p>MSCs dose: less than 2 × 10⁷/kg; 2 × 10⁷/kg or greater;</p> </li> <li> <p>number of doses: multiple or single administration;</p> </li> <li> <p>passage number (i.e. removing cells from a culture flask and plating them into more culture flasks; see <a href="#CD013202-sec-0010">Description of the intervention</a>): less than three; three to six; greater than six. </p> </li> </ul> </p> <p>For other cell‐based interventions:</p> <p> <ul id="CD013202-list-0034"> <li> <p>gestational age: term infants (≥ 37 weeks' gestation), late preterm infants (34 to 36+6 weeks' gestation); </p> </li> <li> <p>HIE severity stage: mild, moderate and severe (Sarnat);</p> </li> <li> <p>chronological age: less than three days, three days or greater;</p> </li> <li> <p>co‐intervention: with/without cooling;</p> </li> <li> <p>cell source: bone marrow, cord blood, peripheral blood, placenta;</p> </li> <li> <p>type of graft: autologous or allogeneic;</p> </li> <li> <p>fresh or frozen and thawed;</p> </li> <li> <p>number of doses: multiple or single administration.</p> </li> </ul> </p> </section> <section id="CD013202-sec-0047"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to explore the effect of the methodological quality of trials, checking to ascertain whether studies with a high risk of bias would overestimate the effect of treatment. Differences in study design of included trials might affect the results of the systematic review. We planned to perform a sensitivity analysis to compare the effects of MSCs in truly randomised trials as opposed to quasi‐randomised trials. </p> </section> <section id="CD013202-sec-0048"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We planned to use the GRADE approach to assess the quality of evidence for the following (clinically relevant) outcomes (<a href="./references#CD013202-bbs2-0131" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>): 1) All‐cause neonatal mortality (mortality less than 28 days of age); 2) Major neurodevelopmental disability: cerebral palsy, developmental delay (Bayley Mental Developmental Index or Griffiths Mental Development Scale assessment greater than two standard deviations (SD) below the mean), intellectual impairment (intelligence quotient (IQ) greater than two SDs below the mean), blindness (vision less than 6/60 in both eyes), or sensorineural deafness requiring amplification; 3) Death or major neurodevelopmental disability assessed at 18 to 24 months of age (defined as cerebral palsy, developmental delay (Bayley or Griffith assessment more than two SD below the mean) or intellectual impairment (IQ more than two SD below mean), blindness (vision less than 6/60 in both eyes), or sensorineural deafness requiring amplification; 4) All‐cause mortality prior to first hospital discharge; 5) cognitive development (Bayley Scales of Infant Development – Mental Development Index (BSID MDI)) assessed in survivors; 6) seizures or need for anticonvulsants at follow‐up 12 to 14 months of age; 7) Immune‐rejection or any serious adverse event (certain, probable or possible according to the WHO probability scale). </p> <p>We planned to independently assess the quality of the evidence for each of the seven outcomes above. We planned to consider evidence from RCTs as high quality but downgrade the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias); consistency across studies; directness of the evidence; precision of estimates; and presence of publication bias. We planned to use the <a href="./references#CD013202-bbs2-0058" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 09 January 2018. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a> Guideline Development Tool to create a 'Summary of findings' table to report the quality of the evidence. </p> <p>The GRADE approach results in an assessment of the quality of a body of evidence in one of four grades. </p> <p> <ul id="CD013202-list-0035"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013202-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013202-sec-0049"></div> <section id="CD013202-sec-0050"> <h3 class="title">Description of studies</h3> <p>We have provided results of the search for this review in the study flow diagram (<a href="#CD013202-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013202-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013202-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013202.pub2/media/CDSR/CD013202/image_n/nCD013202-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <p>See <a href="./references#CD013202-sec-0081" title="">Characteristics of excluded studies</a>, <a href="./references#CD013202-sec-0083" title="">Characteristics of ongoing studies</a> and <a href="./references#CD013202-sec-0082" title="">Characteristics of awaiting studies</a>. </p> <section id="CD013202-sec-0051"> <h4 class="title">Results of the search</h4> <p>The literature search run in June 2020 identified 616 references. Upon screening, we considered no trials as potentially eligible. </p> <p>Three phase 1 studies are currently registered on our targeted patient group and reported in the <a href="#CD013202-sec-0053">Excluded studies</a> and <a href="./references#CD013202-sec-0081" title="">Characteristics of excluded studies</a> sections (<a href="./references#CD013202-bbs2-0001" title="CottenCM ,  MurthaAP ,  GoldbergRN ,  GrotegutCA ,  SmithPB ,  GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a>; <a href="./references#CD013202-bbs2-0002" title="Cotten CM, FisherK ,  Kurtzberg J,  SimmonsR . Phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Cytotherapy2020;22(5):S192. ">Cotten 2020</a>; <a href="./references#CD013202-bbs2-0003" title="Tsuji M,  Sawada M,  Watabe S, Sano H,  Kanai M, TanakaE , et al. Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety. Scientific reports 20202;10(1):4603. ">Tsuji 2020</a>). </p> <p>Our search of ClinicalTrials.gov, ICTRP/WHO and ISRCTN registry identified 29, 16 and 12 registered studies, respectively. Fifteen ongoing trials were eligible (<a href="./references#CD013202-bbs2-0006" title="ACTRN12610000421033. Autologous umbilical cord blood mononuclear layer transfusion for neonates with encephalopathy: a pilot feasibility study [Efficacy of autologous umbilical cord blood mononuclear layer transfusion to prevent brain injury after neonatal encephalopathy]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12610000421033 (first received 26 May 2010). ">ACTRN12610000421033</a>; <a href="./references#CD013202-bbs2-0007" title="ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TNRC-11001591 (first received 17 August 2011). ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. www.chictr.org.cn/showprojen.aspx?proj=7950 (first received 17 August 2011). ">ChiCTR‐TNRC‐11001591</a>; <a href="./references#CD013202-bbs2-0008" title="ChiCTR-TRC-10000922. Autologous transplantation of cord blood derived stem cells for neonatal hypoxic - ischemic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-10000922 (first received 26 June 2010). ">ChiCTR‐TRC‐10000922</a>; <a href="./references#CD013202-bbs2-0009" title="NCT00593242. Cord blood for neonatal hypoxic-ischemic encephalopathy. clinicaltrials.gov/ct2/show/record/NCT00593242?term=NCT00593242&amp;rank=1 (first received 14 January 2008). ">NCT00593242</a>; <a href="./references#CD013202-bbs2-0011" title="NCT01506258. Autologous stem cells in newborns with oxygen deprivation [Effects of the infusion of autologous non-cryopreserved CD34+ cells in newborns with asphyxia]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01506258 (first received 1 May 2012). NCT01506258. Autologous stem cells in newborns with oxygen deprivation. clinicaltrials.gov/ct2/show/record/NCT01506258?term=NCT01506258&amp;rank=1 (first received 9 January 2012). ">NCT01506258</a>; <a href="./references#CD013202-bbs2-0012" title="NCT01649648. Autologous cord blood cells for brain injury in term newborns. clinicaltrials.gov/ct2/show/NCT01649648?term=NCT01649648&amp;rank=1 (first received 9 January 2012). ">NCT01649648</a>; <a href="./references#CD013202-bbs2-0013" title="JPRN-UMIN000014903. A pilot feasibility and safety study of autologous umbilical cord blood cell therapy in infants with neonatal encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014903 (first received 26 August 2014). NCT02256618. A pilot feasibility and safety study of autologous umbilical cord blood cell therapy in infants with neonatal encephalopathy. ichgcp.net/clinical-trials-registry/NCT02256618 (first received 1 August 2014). ">NCT02256618</a>; <a href="./references#CD013202-bbs2-0014" title="NCT02434965. Autologous cord blood and human placental derived stem cells in neonates with severe hypoxic-ischemic encephalopathy (HPDSC+HIE). clinicaltrials.gov/ct2/show/record/NCT02434965?term=NCT02434965&amp;rank=1 (first received 6 May 2015). ">NCT02434965</a>; <a href="./references#CD013202-bbs2-0015" title="NCT02455830. Cytokines associated with cord blood cell therapy for neonatal encephalopathy. clinicaltrials.gov/ct2/show/record/NCT02455830?term=NCT02455830&amp;rank=1 (first received 28 May 2015). ">NCT02455830</a>; <a href="./references#CD013202-bbs2-0016" title="NCT02612155. A multi-site study of autologous cord blood cells for hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/nct02612155 (first received 23 November 2015). ">NCT02612155</a>; <a href="./references#CD013202-bbs2-0017" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579?term=NCT02854579&amp;rank=1 (first received 3 August 2016). Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy (HIE). apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02854579 (first received 23 November 2015). ">NCT02854579</a>; <a href="./references#CD013202-bbs2-0018" title="NCT02881970. Neonatal hypoxic ischemic encephalopathy: safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOSTEM). clinicaltrials.gov/ct2/show/record/NCT02881970?term=NCT02881970&amp;rank=1 (first received 29 August 2016). NCT02881970. Neonatal hypoxic ischemic encephalopathy: safety and feasibility study of a curative treatment with autologous cord blood stem cells NEOSTEM. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02881970 (first received 20 April 2017). ">NCT02881970</a>; <a href="./references#CD013202-bbs2-0019" title="NCT03352310. Feasibility and safety of umbilical cord blood transfusion in the treatment of neonatal cerebral ischemia and anemia. clinicaltrials.gov/ct2/show/record/NCT03352310?term=NCT03352310&amp;rank=1 (first received 24 November 2017). ">NCT03352310</a>; <a href="./references#CD013202-bbs2-0020" title="NCT03635450. Study of hCT-MSC in newborn infants with moderate or severe HIE. clinicaltrials.gov/ct2/show/record/NCT03635450?term=NCT03635450&amp;rank=1 (first received 17 August 2018). ">NCT03635450</a>; <a href="./references#CD013202-bbs2-0010" title="NCT01284673. Characterization of the cord blood stem cell in situation of neonatal asphyxia (NEOCORD). clinicaltrials.gov/ct2/show/record/NCT01284673?term=NCT01284673&amp;rank=1 (first received 27 January 2011). "> NCT01284673</a>). See <a href="./references#CD013202-sec-0083" title="">Characteristics of ongoing studies</a>. </p> <p>We classified two studies as awaiting classification: in <a href="./references#CD013202-bbs2-0004" title="CottenCM , MurthaA , GoldbergR , SmithPB , GrotegutC , GoldsteinRF , et al. Autologous cord blood cells for infants with hypoxic-ischemic encephalopathy (HIE): a feasibility study. In: Pediatric Academic Societies (PAS) Annual Meeting; 2011 April 30 to May 3; Denver (CO). 2011. ">Cotten 2011</a> the abstract and the full text were not available; in <a href="./references#CD013202-bbs2-0005" title="NabetaniM , ShintakuH , TsujiM , TamuraM , KusudaS , HayakawaM , et al. Clinical trial study of autologous cord blood cell therapy for newborn with hypoxic ischemic encephalopathy in Japan. In: European Journal of Pediatrics. 6th Congress of the European Academy of Paediatric Societies; 2016 Oct 21-24; Geneva (Switzerland). 2016. ">Nabetani 2016</a> outcomes were not reported in the abstract and the full text was not available (see <a href="./references#CD013202-sec-0082" title="">Characteristics of studies awaiting classification</a>). </p> </section> <section id="CD013202-sec-0052"> <h4 class="title">Included studies</h4> <p>We identified no trials that matched our inclusion criteria. </p> </section> <section id="CD013202-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded three studies (<a href="./references#CD013202-bbs2-0001" title="CottenCM ,  MurthaAP ,  GoldbergRN ,  GrotegutCA ,  SmithPB ,  GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a>; <a href="./references#CD013202-bbs2-0002" title="Cotten CM, FisherK ,  Kurtzberg J,  SimmonsR . Phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Cytotherapy2020;22(5):S192. ">Cotten 2020</a>; <a href="./references#CD013202-bbs2-0003" title="Tsuji M,  Sawada M,  Watabe S, Sano H,  Kanai M, TanakaE , et al. Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety. Scientific reports 20202;10(1):4603. ">Tsuji 2020</a>). See <a href="./references#CD013202-sec-0081" title="">Characteristics of excluded studies</a>). </p> <p><a href="./references#CD013202-bbs2-0001" title="CottenCM ,  MurthaAP ,  GoldbergRN ,  GrotegutCA ,  SmithPB ,  GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a> was a phase 1 open‐label study in 23 infants (greater than or equal to 35 weeks of gestation) fulfilling the criteria for HIE and needing hypothermia treatment. Hypothermia criteria were met if infants had cord or first postnatal hour blood gas results with pH of 7.0 or less, or base deficit equal to or more than −16. Cord blood was collected aseptically via in utero or ex utero techniques by trained staff. Infants were pretreated with 1 mg/kg hydrocortisone, intravenously, and then received up to four infusions of 1 to 5 × 10⁷ cells/kg, with the first dose as soon as possible after birth, and at 24, 48, and 72 postnatal hours. Cells were infused over 15 to 20 minutes, followed by a 1 mL to 2 mL saline flush to clear the intravascular line. Twenty‐three infants were treated with both hypothermia and autologous injection of UCB cells. Eleven infants received four infusions; three infants three infusions; six infants two infusions; and three infants one infusion. Three infants required extracorporeal membrane oxygenation and four infants required seizure medications at discharge. </p> <p><a href="./references#CD013202-bbs2-0002" title="Cotten CM, FisherK ,  Kurtzberg J,  SimmonsR . Phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Cytotherapy2020;22(5):S192. ">Cotten 2020</a> was a phase 1 open‐label study of umbilical cord tissue‐derived MSCs in infants treated with hypothermia for HIE. Infants of more than 35 weeks' gestation treated with hypothermia for HIE based on NICHD hypothermia trial criteria were eligible. Allogeneic umbilical cord tissue‐derived mesenchymal stromal cells (hCT‐MSC) were manufactured from a single cord tissue. Cells were expanded to passage 2 and cryopreserved. The first three infants (cohort 1) received 2 × 106 cells/kg intravenously in the first 48 postnatal hours; the second three (cohort 2) received a second dose at two months. Primary safety outcomes were occurrence of infusion reactions or infections within two weeks of infusion. Six infants (birthweight 2.74 kg to 4.4 kg)  were enrolled. Apgar scores ranged from 2 to 6 and 3 to 8 at 5 and 10 minutes, respectively. One of the infants had a positive panel reactive antibody (PRA) screen at six months. Broth culture from thawed hCT‐MSC from an infant grew coagulase‐negative staphylococci; the infant remained asymptomatic after re‐warming and the infant's blood cultures were sterile. Length of stay was between 9 and 10 days for all infants; none was re‐hospitalized. </p> <p><a href="./references#CD013202-bbs2-0003" title="Tsuji M,  Sawada M,  Watabe S, Sano H,  Kanai M, TanakaE , et al. Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety. Scientific reports 20202;10(1):4603. ">Tsuji 2020</a> was a phase 1 open‐label study of intravenous infusion of autologous umbilical cord blood cells to newborns with HIE. When a neonate was born with severe asphyxia following caesarean section, the UCB was collected, volume‐reduced, and divided into three doses. The concentration of CD34+ cells/microliter ranged between 17 and 539 per dose, which were infused at 12 to 24, 36 to 48, and 60 to 72 hours after the birth to each infant. At 30 days of age, the six infants survived without circulatory or respiratory support; at 18 months of age, neurofunctional development according to the Kyoto Scale of Psychological Development was normal in four infants and delayed with cerebral palsy in two infants. </p> <section id="CD013202-sec-0054"> <h5 class="title">Ongoing studies</h5> <p>We found 15 relevant studies on the clinical trials registries for ongoing or recently completed trials  (<a href="./references#CD013202-bbs2-0007" title="ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TNRC-11001591 (first received 17 August 2011). ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. www.chictr.org.cn/showprojen.aspx?proj=7950 (first received 17 August 2011). ">ChiCTR‐TNRC‐11001591</a>; <a href="./references#CD013202-bbs2-0008" title="ChiCTR-TRC-10000922. Autologous transplantation of cord blood derived stem cells for neonatal hypoxic - ischemic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-10000922 (first received 26 June 2010). ">ChiCTR‐TRC‐10000922</a>; <a href="./references#CD013202-bbs2-0013" title="JPRN-UMIN000014903. A pilot feasibility and safety study of autologous umbilical cord blood cell therapy in infants with neonatal encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014903 (first received 26 August 2014). NCT02256618. A pilot feasibility and safety study of autologous umbilical cord blood cell therapy in infants with neonatal encephalopathy. ichgcp.net/clinical-trials-registry/NCT02256618 (first received 1 August 2014). ">NCT02256618</a>; <a href="./references#CD013202-bbs2-0016" title="NCT02612155. A multi-site study of autologous cord blood cells for hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/nct02612155 (first received 23 November 2015). ">NCT02612155</a>; <a href="./references#CD013202-bbs2-0017" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579?term=NCT02854579&amp;rank=1 (first received 3 August 2016). Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy (HIE). apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02854579 (first received 23 November 2015). ">NCT02854579</a>; <a href="./references#CD013202-bbs2-0014" title="NCT02434965. Autologous cord blood and human placental derived stem cells in neonates with severe hypoxic-ischemic encephalopathy (HPDSC+HIE). clinicaltrials.gov/ct2/show/record/NCT02434965?term=NCT02434965&amp;rank=1 (first received 6 May 2015). ">NCT02434965</a>; <a href="./references#CD013202-bbs2-0009" title="NCT00593242. Cord blood for neonatal hypoxic-ischemic encephalopathy. clinicaltrials.gov/ct2/show/record/NCT00593242?term=NCT00593242&amp;rank=1 (first received 14 January 2008). ">NCT00593242</a>; <a href="./references#CD013202-bbs2-0011" title="NCT01506258. Autologous stem cells in newborns with oxygen deprivation [Effects of the infusion of autologous non-cryopreserved CD34+ cells in newborns with asphyxia]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01506258 (first received 1 May 2012). NCT01506258. Autologous stem cells in newborns with oxygen deprivation. clinicaltrials.gov/ct2/show/record/NCT01506258?term=NCT01506258&amp;rank=1 (first received 9 January 2012). ">NCT01506258</a>; <a href="./references#CD013202-bbs2-0020" title="NCT03635450. Study of hCT-MSC in newborn infants with moderate or severe HIE. clinicaltrials.gov/ct2/show/record/NCT03635450?term=NCT03635450&amp;rank=1 (first received 17 August 2018). ">NCT03635450</a>; <a href="./references#CD013202-bbs2-0015" title="NCT02455830. Cytokines associated with cord blood cell therapy for neonatal encephalopathy. clinicaltrials.gov/ct2/show/record/NCT02455830?term=NCT02455830&amp;rank=1 (first received 28 May 2015). ">NCT02455830</a>; <a href="./references#CD013202-bbs2-0018" title="NCT02881970. Neonatal hypoxic ischemic encephalopathy: safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOSTEM). clinicaltrials.gov/ct2/show/record/NCT02881970?term=NCT02881970&amp;rank=1 (first received 29 August 2016). NCT02881970. Neonatal hypoxic ischemic encephalopathy: safety and feasibility study of a curative treatment with autologous cord blood stem cells NEOSTEM. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02881970 (first received 20 April 2017). ">NCT02881970</a>; <a href="./references#CD013202-bbs2-0012" title="NCT01649648. Autologous cord blood cells for brain injury in term newborns. clinicaltrials.gov/ct2/show/NCT01649648?term=NCT01649648&amp;rank=1 (first received 9 January 2012). ">NCT01649648</a>; <a href="./references#CD013202-bbs2-0010" title="NCT01284673. Characterization of the cord blood stem cell in situation of neonatal asphyxia (NEOCORD). clinicaltrials.gov/ct2/show/record/NCT01284673?term=NCT01284673&amp;rank=1 (first received 27 January 2011). "> NCT01284673</a>; <a href="./references#CD013202-bbs2-0019" title="NCT03352310. Feasibility and safety of umbilical cord blood transfusion in the treatment of neonatal cerebral ischemia and anemia. clinicaltrials.gov/ct2/show/record/NCT03352310?term=NCT03352310&amp;rank=1 (first received 24 November 2017). ">NCT03352310</a>; <a href="./references#CD013202-bbs2-0006" title="ACTRN12610000421033. Autologous umbilical cord blood mononuclear layer transfusion for neonates with encephalopathy: a pilot feasibility study [Efficacy of autologous umbilical cord blood mononuclear layer transfusion to prevent brain injury after neonatal encephalopathy]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12610000421033 (first received 26 May 2010). ">ACTRN12610000421033</a>; see <a href="./references#CD013202-sec-0083" title="">Characteristics of ongoing studies</a>). Nine studies consist of single group assignment studies, whereas we will pool the remaining six studies in comparison 1 of this review, i.e. stem cell‐based interventions versus placebo or no treatment (<a href="./references#CD013202-bbs2-0007" title="ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TNRC-11001591 (first received 17 August 2011). ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. www.chictr.org.cn/showprojen.aspx?proj=7950 (first received 17 August 2011). ">ChiCTR‐TNRC‐11001591</a>; <a href="./references#CD013202-bbs2-0008" title="ChiCTR-TRC-10000922. Autologous transplantation of cord blood derived stem cells for neonatal hypoxic - ischemic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-10000922 (first received 26 June 2010). ">ChiCTR‐TRC‐10000922</a>; <a href="./references#CD013202-bbs2-0016" title="NCT02612155. A multi-site study of autologous cord blood cells for hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/nct02612155 (first received 23 November 2015). ">NCT02612155</a>; <a href="./references#CD013202-bbs2-0011" title="NCT01506258. Autologous stem cells in newborns with oxygen deprivation [Effects of the infusion of autologous non-cryopreserved CD34+ cells in newborns with asphyxia]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01506258 (first received 1 May 2012). NCT01506258. Autologous stem cells in newborns with oxygen deprivation. clinicaltrials.gov/ct2/show/record/NCT01506258?term=NCT01506258&amp;rank=1 (first received 9 January 2012). ">NCT01506258</a>; <a href="./references#CD013202-bbs2-0019" title="NCT03352310. Feasibility and safety of umbilical cord blood transfusion in the treatment of neonatal cerebral ischemia and anemia. clinicaltrials.gov/ct2/show/record/NCT03352310?term=NCT03352310&amp;rank=1 (first received 24 November 2017). ">NCT03352310</a>; <a href="./references#CD013202-bbs2-0017" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579?term=NCT02854579&amp;rank=1 (first received 3 August 2016). Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy (HIE). apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02854579 (first received 23 November 2015). ">NCT02854579</a>). The latter will have four study arms, with the following interventions given intrathecally: neural progenitor cells; paracrine factors of human MSCs; concentrated paracrine factor plus neural progenitor cell; routine therapy. </p> <section id="CD013202-sec-0055"> <h6 class="title">Description of the 15 ongoing studies</h6> <p><a href="./references#CD013202-bbs2-0007" title="ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TNRC-11001591 (first received 17 August 2011). ChiCTR-TNRC-11001591. Early intervention of stem cell transplantation for neonates with hypoxic-ischemic encephalpathy----a preliminary clinical study. www.chictr.org.cn/showprojen.aspx?proj=7950 (first received 17 August 2011). ">ChiCTR‐TNRC‐11001591</a> is a phase 1 non‐randomised control interventional study, aiming to compare routine care plus stem cells versus routine care plus rehabilitation. Both groups will include 10 full‐term infants with an Apgar score at 5 minutes of less than 6 and at 10 minutes of less than 5, neonatal behavioural neurological assessment (NBNA) score less than 28. Outcome measures (all indicated as primary indicators) will be: infant development test of Child Development Centre of China (CDCC), Gross Motor Function Measure (GMFM), movement Assessment Battery for Children (ABC), visual evoke potentials, brainstem auditory evoked potentials, somatosensory evoked potentials, NBNA, fine motor function measure (FMFM), EEG. </p> <p><a href="./references#CD013202-bbs2-0008" title="ChiCTR-TRC-10000922. Autologous transplantation of cord blood derived stem cells for neonatal hypoxic - ischemic encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR-TRC-10000922 (first received 26 June 2010). ">ChiCTR‐TRC‐10000922</a> was registered retrospectively. It is a parallel interventional study with two arms: conventional treatment plus autologous transplantation of cord blood versus conventional treatment. Each arm includes 20 neonates within 24 hours of birth, with cord pH during birth less than 7.0, Apgar's score less than 7 (not specified at which minute) and showing HIE presentation (criteria not specified). Primary indicator outcome measurements are: EEG, intellectual and behavioural development (scales are not specified), neuron specific enolase (NSE), diffusion‐weighted imaging (DWI). Secondary indicators for outcomes are: clinical presentations and blood routine, urine routine, liver function and kidney function.  </p> <p><a href="./references#CD013202-bbs2-0013" title="JPRN-UMIN000014903. A pilot feasibility and safety study of autologous umbilical cord blood cell therapy in infants with neonatal encephalopathy. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000014903 (first received 26 August 2014). NCT02256618. A pilot feasibility and safety study of autologous umbilical cord blood cell therapy in infants with neonatal encephalopathy. ichgcp.net/clinical-trials-registry/NCT02256618 (first received 1 August 2014). ">NCT02256618</a> is an open‐label interventional study with one group assignment. Six newborns of 36 weeks' or more gestational age (GA) with either Apgar score of 5 or less at 10 minutes or severe acidosis at umbilical or any blood during the first hour after birth, defined as pH less than 7.0 or base deficit of 16 mmol/L or more, moderate or severe HIE (Sarnat II to III),  a moderately or severely abnormal background amplitude‐integrated EEG (aEEG) voltage, or seizures identified by aEEG, if monitored will be included.  All infants should be less than 24 hours of age. Primary outcome of this study is the rate of adverse events (combined rate of death, continuous respiratory support, and continuous use of vasopressor), which will be compared with historical controls at 30 days of age. Secondary outcomes are neuroimaging at 12 months of age and neurodevelopmental function at 18 months of age (comparison with historical controls). </p> <p><a href="./references#CD013202-bbs2-0016" title="NCT02612155. A multi-site study of autologous cord blood cells for hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/nct02612155 (first received 23 November 2015). ">NCT02612155</a> is a phase 2 interventional randomised trial, aiming to include 160 newborns with GA greater than or equal to 36 weeks and having less than 6 hours of life with following criteria fulfilled: a cord blood or any blood within the first hour of life with a pH less than or equal to 7.0 or a base deficit (BE) greater than or equal to 16 mmol/L. If, during this time period, a pH was between 7.01 to 7.15 and BE between 10 to 15.9 mmol/L, or non‐available blood gas, additional criteria were: an acute perinatal event (e.g. late or variable decelerations, cord prolapse, cord rupture, uterine rupture, maternal trauma, haemorrhage, or cardiorespiratory arrest) and either Apgar score less than or equal to 5 at 10 minutes or assisted ventilation initiated at birth and continued for at least 10 minutes. Newborns will be randomised in two groups: hypothermia plus two infusions of autologous nucleated cord blood cells versus hypothermia plus placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Primary outcome measures are:  survival at one year; percentage of subjects with Bayley III scores in all three domains greater than or equal to 85. Secondary outcome measurements at one year of life are currently: mortality rate, percentage of subjects with seizures, percentage of subjects who require iNO use, percentage of subjects who require ECMO, percentage of subjects who require G‐tube feeding, percentage of subjects who discharged with anticonvulsant treatment. </p> <p><a href="./references#CD013202-bbs2-0017" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579?term=NCT02854579&amp;rank=1 (first received 3 August 2016). Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy (HIE). apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02854579 (first received 23 November 2015). ">NCT02854579</a> is a randomised open‐labelled study where newborns with gestational age of 34 weeks or more and body weight of 2 kg or more will be enrolled. The inclusion criteria are 1‐ and 5‐minute Apgar score of 3 or less and 5 or less, respectively, or need for ventilation 5 minutes after birth, or umbilical blood pH less than 7.0 or BE of −12 mmol/L or less at 30 minutes. Infants should have signs of encephalopathy (convulsion, coma, dystonia, abnormal primitive reflex and irregular respiration) within six hours of age or continued abnormal EEG for more than 24 hours. Randomisation in four arms is planned:  1) routine therapy plus neural progenitor cells intrathecally at 48 to 72 hours, 5 days and 10 days after birth; 2) routine therapy plus paracrine factors of human MSCs intrathecally at 12 hours, 24 hours, 48 hours after birth; 3) routine therapy plus concentrated paracrine factor intrathecally at 12 hours, 24 hours, 48 hours after birth plus neural progenitor cell intrathecally at 48 to 72 hours, 5 days and 10 days after birth; 4) routine therapy. Primary outcomes are defined as: Neonatal Behavioral Neurological Assessment at 14 and 28 days of life, number of adverse events (fever, seizures, haemorrhage caused by interventions) at 7 days following cells/factors injection. Secondary outcomes  are: Bayley score at 12 and at 18 months after birth, Peabody development measure scale at 12 and at 18 months after birth, death within a year, treatment‐related central nervous tumour as assessed by MRI or CT within 5 years. </p> <p><a href="./references#CD013202-bbs2-0014" title="NCT02434965. Autologous cord blood and human placental derived stem cells in neonates with severe hypoxic-ischemic encephalopathy (HPDSC+HIE). clinicaltrials.gov/ct2/show/record/NCT02434965?term=NCT02434965&amp;rank=1 (first received 6 May 2015). ">NCT02434965</a> is a phase 2 open‐label interventional study with following inclusion criteria: GA of 36 weeks or more and BW of 1800 grams or more, postnatal age less than 6 hours after birth, autologous cord blood and human placental‐derived stem cells (HPDSCs) available for infusion and one or more of the following criteria: Apgar score at 10 minutes of 5 or less, or need for resuscitation 10 minutes or more after birth, or cord blood pH or arterial blood pH within 60 minutes of birth of 7.0 or less, or BE of −16 or more mEq in cord blood and within 60 minutes of birth, and moderate to severe altered state of consciousness (hypotonia, abnormal reflexes, absent/weak suck). Twenty newborns will be assigned to one arm and treated with autologous HPDSC in combination with autologous cord blood. </p> <p><a href="./references#CD013202-bbs2-0009" title="NCT00593242. Cord blood for neonatal hypoxic-ischemic encephalopathy. clinicaltrials.gov/ct2/show/record/NCT00593242?term=NCT00593242&amp;rank=1 (first received 14 January 2008). ">NCT00593242</a> is a phase 1 open‐label non‐randomised interventional study in which newborns are included with GA more than 34 weeks, a history of acute perinatal event or blood pH less than 7.0/BE more than 16 mEq/L, Apgar score at 10 minutes less than 5 or continued need for ventilation. All newborns should present signs of encephalopathy within six hours of age. All infants are recruited in autologous cord blood infusion and they are compared with historical cohort receiving standard treatment. Primary outcome measure is the rate of adverse events within the first 18 postnatal days. Secondary outcomes are neurodevelopmental outcome at 4 to 6 months and 9 to 12 months of age (scales not specified) plus neuroimaging results (not specified). </p> <p><a href="./references#CD013202-bbs2-0011" title="NCT01506258. Autologous stem cells in newborns with oxygen deprivation [Effects of the infusion of autologous non-cryopreserved CD34+ cells in newborns with asphyxia]. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01506258 (first received 1 May 2012). NCT01506258. Autologous stem cells in newborns with oxygen deprivation. clinicaltrials.gov/ct2/show/record/NCT01506258?term=NCT01506258&amp;rank=1 (first received 9 January 2012). ">NCT01506258</a> is an open‐label non‐randomised study with parallel assignment of full‐term (GA 37 to 42 weeks) with neurological manifestations compatible with HIE, 5‐minute Apgar score less than 5, pH less than 7.0 at cord blood gas and any degree of organic/systemic affectation (cardiovascular, gastrointestinal, hematologic and/or respiratory) either in intervention group (intravascular infusion of autologous stem cells within the first 48 hours after birth) or in comparison group (control group of patients that meet the inclusion criteria but that do not wish to have the intervention). Primary outcome is the effects of stem cell infusion at one week and one year after discharge (clinical assessment, including the Amiel‐Tison Neurological Assessment). No secondary outcomes are listed. </p> <p><a href="./references#CD013202-bbs2-0020" title="NCT03635450. Study of hCT-MSC in newborn infants with moderate or severe HIE. clinicaltrials.gov/ct2/show/record/NCT03635450?term=NCT03635450&amp;rank=1 (first received 17 August 2018). ">NCT03635450</a> is a phase 1 open‐label, non‐randomised, parallel assignment study. A total of six newborns with GA of 36+0 or more with signs of encephalopathy within six hours of age will be included. The first cohort newborns (N = 3) will receive a single infusion of human umbilical cord tissue (hCT)‐derived MSC within 48 hours after birth. If no safety concerns appear, the second cohort infants will receive two infusions of umbilical‐cord‐derived MSCs within the first 48 hours and 2 months later, respectively. Primary outcomes of the study are the allergic reactions within 24 hours following hCT‐MSC infusion and the rate of infections within two weeks' post‐infusion. Secondary outcomes are the survival within six months and neurodevelopmental assessment at one year of age (Bayley Scales of Infant and Toddler Development, Third Edition (Bayley III)), assessments in cognitive, language and motor development. </p> <p><a href="./references#CD013202-bbs2-0015" title="NCT02455830. Cytokines associated with cord blood cell therapy for neonatal encephalopathy. clinicaltrials.gov/ct2/show/record/NCT02455830?term=NCT02455830&amp;rank=1 (first received 28 May 2015). ">NCT02455830</a> is a prospective, case‐control, observational study which will include 18 neonates with GA greater than or equal to 36 weeks up to 24 hours of age who will present with moderate to severe encephalopathy (Sarnat II to III) and either an Apgar score of 5 or less at 10 minutes, continued need for resuscitation for at least 10 minutes, or severe acidosis in cord blood or any blood gas during the first postnatal hour (pH less than 7.0 or BE  greater than or equal to ‐16 mmol/L). The primary outcome of the study is changes in serum levels of cytokines and trophic factors within the first 10 days of life. Secondary outcomes for the study are neuroimaging at 12 months of age (it is not specified what kind of neuroimaging will be used and what kind of analysis will be done) and neurobehavioural assessment at 18 months of age (scales not specified). </p> <p><a href="./references#CD013202-bbs2-0018" title="NCT02881970. Neonatal hypoxic ischemic encephalopathy: safety and feasibility study of a curative treatment with autologous cord blood stem cells (NEOSTEM). clinicaltrials.gov/ct2/show/record/NCT02881970?term=NCT02881970&amp;rank=1 (first received 29 August 2016). NCT02881970. Neonatal hypoxic ischemic encephalopathy: safety and feasibility study of a curative treatment with autologous cord blood stem cells NEOSTEM. apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02881970 (first received 20 April 2017). ">NCT02881970</a> is a phase 1/2 open‐label, one group assignment study, where neonates who meet the following criteria will be included: GA greater than or equal to 36 weeks with a blood pH less than 7 and BE more than −12 mmol/l at birth or within the first postnatal hour or a blood pH between 7.01 and 7.15 and a history of acute perinatal event and Apgar score at 5 minutes of 5 or less, or a continued need for resuscitation at 5 minutes after birth. Included neonates should have signs of HIE within 12 hours of age (Sarnat and Sarnat classification score greater than or equal to 2) with or without abnormal EEG or aEEG within 12 hours of age and require therapeutic hypothermia. All included infants will receive treatment with autologous cord blood stem cells. The primary outcome of the study is the rate of adverse events due to intervention with a time frame of two years. Secondary outcomes are the neuroimaging (currently not specified what kind and which analysis will be performed) at 12 months of age and neurobehavioral assessment at 18 months of age (scales are not specified). </p> <p><a href="./references#CD013202-bbs2-0012" title="NCT01649648. Autologous cord blood cells for brain injury in term newborns. clinicaltrials.gov/ct2/show/NCT01649648?term=NCT01649648&amp;rank=1 (first received 9 January 2012). ">NCT01649648</a> is a phase 1, open‐label, single group assignment study. Neonates with GA of more than 36 weeks and brain injury satisfying criteria for therapeutic hypothermia (not specified) will be included in the study. All included infants will receive autologous cord blood infusion. The primary outcome of the study is the rate of adverse events during the first three days of life. The secondary outcomes are neurobehavioural assessment (Peabody tests, Bayley Scales of Infant Development) at one month to two years of age and brain MRI at one to two weeks and four to six months of age. </p> <p><a href="./references#CD013202-bbs2-0010" title="NCT01284673. Characterization of the cord blood stem cell in situation of neonatal asphyxia (NEOCORD). clinicaltrials.gov/ct2/show/record/NCT01284673?term=NCT01284673&amp;rank=1 (first received 27 January 2011). "> NCT01284673</a> is an open‐label, single group study aiming to characterise the cord blood stem cells of neonates with neonatal asphyxia (N = 5) and to compare them with those from healthy newborns (N = 5) within two years of life. Ten full‐term infants (GA &gt; 37 weeks) with normal pregnancy and delivery will be included. No secondary outcomes are reported.  </p> <p><a href="./references#CD013202-bbs2-0019" title="NCT03352310. Feasibility and safety of umbilical cord blood transfusion in the treatment of neonatal cerebral ischemia and anemia. clinicaltrials.gov/ct2/show/record/NCT03352310?term=NCT03352310&amp;rank=1 (first received 24 November 2017). ">NCT03352310</a> is a phase 1 non‐randomised study with parallel assignment. Forty infants either with signs of HIE or anaemia will be recruited into the study. The inclusion criteria are: 5‐minute Apgar score of 5 or less; evidence of HIE, defined by UCB pH less than 7.15 or BE of 10 mM or less; subjects with HIE confirmed by clinical features and initial investigations; subjects with evidence of anaemia, defined by haematocrit less than 40% or haemoglobin of 13 g/dL or less within the first 96 hours of life. The comparisons will be standard care plus autologous UCB versus standard care.  Primary outcome of the study is mortality rate in HIE subjects and baseline haematocrit changes in anaemia subjects. Secondary outcomes are listed in <a href="./references#CD013202-sec-0083" title="">Characteristics of ongoing studies</a>. </p> <p><a href="./references#CD013202-bbs2-0006" title="ACTRN12610000421033. Autologous umbilical cord blood mononuclear layer transfusion for neonates with encephalopathy: a pilot feasibility study [Efficacy of autologous umbilical cord blood mononuclear layer transfusion to prevent brain injury after neonatal encephalopathy]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12610000421033 (first received 26 May 2010). ">ACTRN12610000421033</a> is an interventional, single group assignment study. Forty newborns with GA of more than 30 weeks with signs of encephalopathy within the first six hours will be included into the study. Included infants will receive autologous mononuclear cell layer (MNCL) transfusion over 30 minutes. The primary outcome of the study is the rate of adverse events compared to historical controls. Occurrence of blood pressure fluctuation, changes in heart rate, and reaction to blood transfusion will be measured. Secondary outcomes of the study are: MRI score (not specified at which time point) and neurodevelopmental outcome (Bayley II Scales of Infant Development) at four to six and nine to 12 months of age will be compared to historical controls.  </p> </section> <section id="CD013202-sec-0056"> <h6 class="title">Studies in other neonatal populations</h6> <p>The use of stem cell‐based interventions for intraventricular haemorrhage and bronchopulmonary dysplasia is reported in other Cochrane Reviews (<a href="./references#CD013202-bbs2-0124" title="RomantsikO , BruschettiniM , MoreiraA , ThébaudB , LeyD . Stem cell-based interventions for the prevention and treatment of germinal matrix-intraventricular haemorrhage in preterm infants. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013201. [DOI: 10.1002/14651858.CD013201.pub2]">Romantsik 2019</a>; Pierro 2017).  </p> </section> </section> </section> </section> <section id="CD013202-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>No study met the eligibility criteria of this review.</p> </section> <section id="CD013202-sec-0058"> <h3 class="title" id="CD013202-sec-0058">Effects of interventions</h3> <p>No study met the eligibility criteria of this review.</p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013202-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013202-sec-0059"></div> <section id="CD013202-sec-0060"> <h3 class="title" id="CD013202-sec-0060">Summary of main results</h3> <p>Although this review did not identify studies meeting the inclusion criteria, there were 15 early‐phase clinical trials examining the use of stem cell‐based interventions for HIE. Over the next several years these studies will evaluate the safety of MSCs and their impact on neurodevelopment, survival, and brain neuroimaging. The cumulative number of participants will exceed 200 and one of the studies will evaluate brain tumour formation via brain MRI/computed tomography at five years of age (<a href="./references#CD013202-bbs2-0017" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579?term=NCT02854579&amp;rank=1 (first received 3 August 2016). Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy (HIE). apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02854579 (first received 23 November 2015). ">NCT02854579</a>). The number of registered clinical trials suggests that investigators are interested in assessing the therapeutic potential of regenerative therapies for neonatal brain injury. </p> <p>Most trials will be administering autologous umbilical cord blood cells; one study, however, will deliver several doses of neural progenitor cells (<a href="./references#CD013202-bbs2-0017" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579?term=NCT02854579&amp;rank=1 (first received 3 August 2016). Neural progenitor cell and paracrine factors to treat hypoxic ischemic encephalopathy (HIE). apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT02854579 (first received 23 November 2015). ">NCT02854579</a>). Intravenous and intrathecal routes will be modes of delivery. Details of the trials were at times sparse, but some studies will include up to four separate cell administrations with a dose as high as 50 million cells/kg birthweight. The clinical trials will be conducted in seven different countries. </p> <p>We excluded two phase 1 clinical trials on autologous umbilical cord blood cells (<a href="./references#CD013202-bbs2-0001" title="CottenCM ,  MurthaAP ,  GoldbergRN ,  GrotegutCA ,  SmithPB ,  GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a>; <a href="./references#CD013202-bbs2-0003" title="Tsuji M,  Sawada M,  Watabe S, Sano H,  Kanai M, TanakaE , et al. Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety. Scientific reports 20202;10(1):4603. ">Tsuji 2020</a>); and one phase 1 clinical trial on allogeneic umbilical cord tissue‐derived mesenchymal stromal cells (<a href="./references#CD013202-bbs2-0002" title="Cotten CM, FisherK ,  Kurtzberg J,  SimmonsR . Phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Cytotherapy2020;22(5):S192. ">Cotten 2020</a>). In <a href="./references#CD013202-bbs2-0001" title="CottenCM ,  MurthaAP ,  GoldbergRN ,  GrotegutCA ,  SmithPB ,  GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a> 23 infants, with an average gestational age of 38 weeks and birthweight of 3.1 kg, received a dose of 1 to 5 × 10⁷ cells/kg for each infusion; no adverse events were reported, and vital signs were stable during infusions. In <a href="./references#CD013202-bbs2-0002" title="Cotten CM, FisherK ,  Kurtzberg J,  SimmonsR . Phase I trial of allogeneic umbilical cord tissue-derived mesenchymal stromal cells in neonates with hypoxic-ischemic encephalopathy. Cytotherapy2020;22(5):S192. ">Cotten 2020</a> six infants received 2 × 10⁶ cells/kg intravascularly in the first 48 postnatal hours, and three of them a second dose at two months; length of stay was between nine and 10 days for all infants and no adverse events were reported. In <a href="./references#CD013202-bbs2-0003" title="Tsuji M,  Sawada M,  Watabe S, Sano H,  Kanai M, TanakaE , et al. Autologous cord blood cell therapy for neonatal hypoxic-ischaemic encephalopathy: a pilot study for feasibility and safety. Scientific reports 20202;10(1):4603. ">Tsuji 2020</a> six infants were infused daily for three days; at 18 months of age, neurofunctional development was normal in four infants and delayed with cerebral palsy in two infants. </p> <p>At present, no studies have been completed to evaluate the efficacy of stem cell therapies for HIE. Prior to performing phase 3 trials, additional studies evaluating safety and measures of efficacy are required. </p> </section> <section id="CD013202-sec-0061"> <h3 class="title" id="CD013202-sec-0061">Overall completeness and applicability of evidence</h3> <p>We identified no eligible studies for inclusion.</p> </section> <section id="CD013202-sec-0062"> <h3 class="title" id="CD013202-sec-0062">Quality of the evidence</h3> <p>We identified no eligible studies for inclusion.</p> </section> <section id="CD013202-sec-0063"> <h3 class="title" id="CD013202-sec-0063">Potential biases in the review process</h3> <p>We used standard methods of Cochrane Neonatal in conducting this systematic review. It is unlikely that the literature search applied to this review may have missed relevant trials, thus we are confident that this systematic review summarises all the presently available randomised trial evidence on stem cell‐based interventions for HIE. We applied no language restriction. </p> </section> <section id="CD013202-sec-0064"> <h3 class="title" id="CD013202-sec-0064">Agreements and disagreements with other studies or reviews</h3> <p>The use of stem cell‐based interventions for intraventricular haemorrhage and bronchopulmonary dysplasia is reported in other Cochrane Reviews (<a href="./references#CD013202-bbs2-0124" title="RomantsikO , BruschettiniM , MoreiraA , ThébaudB , LeyD . Stem cell-based interventions for the prevention and treatment of germinal matrix-intraventricular haemorrhage in preterm infants. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD013201. [DOI: 10.1002/14651858.CD013201.pub2]">Romantsik 2019</a>; Pierro 2017).  </p> <p>To our knowledge, this is the first systematic review of clinical studies on stem cell‐based interventions for HIE. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013202-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/media/CDSR/CD013202/urn:x-wiley:14651858:media:CD013202:CD013202-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013202-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013202.pub2/media/CDSR/CD013202/image_n/nCD013202-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/media/CDSR/CD013202/image_t/tCD013202-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/media/CDSR/CD013202/image_n/nCD013202-FIG-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD013202-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of regenerative cells</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Cell type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Source</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Rationale</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Mechanism of action</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Preclinical/clinical results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>References</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord tissue/blood; rodent/human bone marrow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safe and feasible in phase 1 RCT for bronchopulmonary dysplasia</p> <p> <ul id="CD013202-list-0001"> <li> <p>Low immunogenicity (low MHC II), easily obtainable, rapid expansion</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0002"> <li> <p>Paracrine release of IGF‐1, EGF, VEGF, BDNF</p> </li> <li> <p>Immunomodulatory: regulate T‐cell, B‐cell function, and production of inflammatory cytokines </p> </li> <li> <p>Mitochondrial transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0003"> <li> <p>Nerve fibre remyelination and axonal regeneration</p> </li> <li> <p>Improve behavioural/motor tests</p> </li> <li> <p>Enhance neural cell proliferation, survival, function</p> </li> <li> <p>Decrease infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0021" title="AhnSY , ChangYS , ParkWS . Stem cells for neonatal brain disorders. Neonatology2016;109(4):377-83. [DOI: 10.1159/000444905] [PMID: 27251746]">Ahn 2016</a>; <a href="./references#CD013202-bbs2-0031" title="BoshuizenMC , SteinbergGK . Stem cell-based immunomodulation after stroke: effects on brain repair processes. Stroke2018;49(6):1563-70.">Boshuizen 2018</a>; <a href="./references#CD013202-bbs2-0035" title="ChoppM , LiY . Treatment of neural injury with marrow stromal cells. Lancet Neurology2002;1(2):92-100. [PMID: 12849513]">Chopp 2002</a>; <a href="./references#CD013202-bbs2-0069" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013202-bbs2-0071" title="IslamMN , DasSR , EminMT , WeiM , SunL , WestphalenK , et al. Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Medicine2012;18(5):759-65.">Islam 2012</a>; <a href="./references#CD013202-bbs2-0085" title="LiuAM , LuG , TsangKS , LiG , WuY , HuangZS , et al. Umbilical cord-derived mesenchymal stem cells with forced expression of hepatocyte growth factor enhance remyelination and functional recovery in a rat intracerebral hemorrhage model. Neurosurgery2010;67(2):357-65; discussion 365-6. [DOI: 10.1227/01.NEU.0000371983.06278.B3] [PMID: 20644422]">Liu 2010</a>; <a href="./references#CD013202-bbs2-0094" title="MurphyMB , MoncivaisK , CaplanAI . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental &amp; Molecular Medicine2013;45:e54. [DOI: 10.1038/emm.2013.94] [PMID: 24232253]">Murphy 2013</a>; <a href="./references#CD013202-bbs2-0107" title="ParkWS , SungSI , AhnSY , SungDK , ImGH , YooHS , et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage. Cell Transplantation2016;25(6):1131-44. [DOI: 10.3727/096368915X689640] [PMID: 26440762]">Park 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MNC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0004"> <li> <p>Readily collected and large supply in cord blood with high plasticity</p> </li> <li> <p>Safe and feasible in phase 1 RCT for hypoxic‐ischaemic encephalopathy</p> </li> <li> <p>Low immunogenicity (minimal HLA matching)</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0005"> <li> <p>Increase expression of BDNF, NGF, VEGF, GDNF</p> </li> <li> <p>Activation of pro‐survival Akt pathway</p> </li> <li> <p>Decrease TNF‐α and increase IL‐10 gene expression</p> </li> <li> <p>Reduce CD4+ T cell infiltration</p> </li> <li> <p>Regulate hedgehog signalling</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0006"> <li> <p>Decrease neuronal apoptosis, astrogliosis, inflammation</p> </li> <li> <p>Improve oligodendrocyte survival</p> </li> <li> <p>Induce axonal growth</p> </li> <li> <p>Improve neurobehavioral outcome</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0023" title="AridasJD , McDonaldCA , PatonMC , YawnoT , SutherlandAE , NitsosI , et al. Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb. Journal of Physiology2016;594(5):1421-35. [DOI: 10.1113/JP271104] [PMID: 26527561]">Aridas 2016</a>; Cotton 2014; <a href="./references#CD013202-bbs2-0049" title="FanCG , ZhangQJ , TangFW , HanZB , WangGS , HanZC . Human umbilical cord blood cells express neurotrophic factors. Neuroscience letters2005;380(3):322-5. [PMID: 15862910]">Fan 2005</a>; <a href="./references#CD013202-bbs2-0089" title="McDonaldCA , PennyTR , PatonMC , SutherlandAE , NekkantiL , YawnoT , et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. Journal of Neuroinflammation2018;15(1):47. [PMID: 29454374]">McDonald 2018</a>; <a href="./references#CD013202-bbs2-0116" title="Pimentel-CoelhoPM , Rosado-de-CastroPH , da FonsecaLM , Mendez-OteroR . Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2012;71(4 Pt 2):464-73. [PMID: 22430382]">Pimentel‐Coelho 2012</a>; <a href="./references#CD013202-bbs2-0126" title="RoweDD , LeonardoCC , HallAA , ShahaduzzamanMD , CollierLA , WillingAE , et al. Cord blood administration induces oligodendrocyte survival through alterations in gene expression. Brain Research2010;1366:172-88. [PMID: 20883670]">Rowe 2010</a>; <a href="./references#CD013202-bbs2-0150" title="WangXL , ZhaoYS , HuMY , SunYQ , ChenYX , BiXH . Umbilical cord blood cells regulate endogenous neural stem cell proliferation via hedgehog signaling in hypoxic ischemic neonatal rats. Brain Research2013;1518:26-35. [PMID: 23632377]">Wang 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rodent/human embryonic stem cell; human NSC derivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0007"> <li> <p>Differentiate into oligodendrocytes (cells highly susceptible to hypoxic‐ischaemic injury) </p> </li> <li> <p>Remyelinate injured axons</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0008"> <li> <p>Diffuse biodistribution along white matter tracts and differentiate into myelin‐sheath‐producing oligodendrocytes </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0009"> <li> <p>Promote myelin sheath formation, NSC proliferation, and inhibit apoptosis</p> </li> <li> <p>Motor recovery following CNS injury</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0034" title="ChenLX , MaSM , ZhangP , FanZC , XiongM , ChengGQ , et al. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury. PloS One2015;10(3):e0115997.">Chen 2015</a>; <a href="./references#CD013202-bbs2-0056" title="GopagondanahalliKR , LiJ , FaheyMC , HuntRW , JenkinG , MillerSL , et al. Preterm hypoxic-ischemic encephalopathy. Frontiers in Pediatrics2016;4:114. [PMID: 27812521]">Gopagondanahalli 2016</a>; <a href="./references#CD013202-bbs2-0079" title="KimTK , ParkD , BanYH , ChaY , AnES , ChoiJ , et al. Improvement by human oligodendrocyte progenitor cells of neurobehavioral disorders in an experimental model of neonatal periventricular leukomalacia. Cell Transplantation2018;27(7):1168-77. [PMID: 29978719]">Kim 2018</a>; <a href="./references#CD013202-bbs2-0088" title="ManleyNC , PriestCA , DenhamJ , Wirth ED 3rd, LebkowskiJS . Human embryonic stem cell-derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Translational Medicine2017;6(10):1917-29. [PMID: 28834391]">Manley 2017</a>; <a href="./references#CD013202-bbs2-0101" title="NiimiY , LevisonSW . Pediatric brain repair from endogenous neural stem cells of the subventricular zone. Pediatric Research2018;83(1-2):385-96. [PMID: 29028220]">Niimi 2018</a>; <a href="./references#CD013202-bbs2-0157" title="XuL , RyuJ , HielH , MenonA , AggarwalA , RhaE , et al. Transplantation of human oligodendrocyte progenitor cells in an animal model of diffuse traumatic axonal injury: survival and differentiation. Stem Cell Research &amp; Therapy2015;6(1):93. [PMID: 25971252]">Xu 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human fetal striatum; human ESC; human iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0010"> <li> <p>Differentiate into cells necessary for brain repair, including: neurons, astrocytes, and oligodendrocytes </p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Low immunogenicity and tumorigenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0011"> <li> <p>Immunomodulation</p> </li> <li> <p>Paracrine secretion of BDNF, VEGF, and EGF</p> </li> <li> <p>Attenuate NF‐κB signalling</p> </li> <li> <p>Upregulate glutamate transport</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0012"> <li> <p>Stimulate survival and migration of endogenous NSCs and neurons</p> </li> <li> <p>Reduce inflammation and reactive oxygen species production</p> </li> <li> <p>Improve axonal growth, motor function, decreased infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0038" title="DaadiMM , KlausnerJQ , BajarB , GoshenI , Lee-MesserC , LeeSY , et al. Optogenetic stimulation of neural grafts enhances neurotransmission and downregulates the inflammatory response in experimental stroke model. Cell Transplantation2016;25(7):1371-80. [PMID: 26132738]">Daadi 2016</a>; <a href="./references#CD013202-bbs2-0070" title="HuangL , ZhangL . Neural stem cell therapies and hypoxic-ischemic brain injury. Progress in Neurobiology 2018 May 21 [Epub ahead of print]. [DOI: 10.1016/j.pneurobio.2018.05.004] [PMID: 29758244]">Huang 2018</a>; <a href="./references#CD013202-bbs2-0075" title="JiG , LiuM , ZhaoXF , LiuXY , GuoQL , GuanZF , et al. NF-kappaB signaling is involved in the effects of intranasally engrafted human neural stem cells on neurofunctional improvements in neonatal rat hypoxic-ischemic encephalopathy. CNS Neuroscience &amp; Therapeutics2015;21(12):926-35. [PMID: 26255634]">Ji 2015</a>; <a href="./references#CD013202-bbs2-0090" title="MineY , TatarishviliJ , OkiK , MonniE , KokaiaZ , LindvallO . Grafted human neural stem cells enhance several steps of endogenous neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiology of Disease2013;52:191-203. [PMID: 23276704]">Mine 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0013"> <li> <p>Paracrine release of neurotrophic factors</p> </li> <li> <p>Multipotent capacity and ability to transdifferentiate into neuronal cells</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0014"> <li> <p>Reduce microglial cells and T lymphocytes</p> </li> <li> <p>Secrete VEGF, HGF, IGF‐1</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0015"> <li> <p>Decrease infarct size and maintains cerebral blood flow</p> </li> <li> <p>Enhance axonal growth</p> </li> <li> <p>Ameliorate neuronal apoptosis and post‐ischaemic inflammation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0130" title="SchwartingS , LitwakS , HaoW , BahrM , WeiseJ , NeumannH . Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke2008;39(10):2867-75. [PMID: 18658037]">Schwarting 2008</a>; <a href="./references#CD013202-bbs2-0142" title="TsujiM , TaguchiA , OhshimaM , KasaharaY , SatoY , TsudaH , et al. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience2014;263:148-58. [PMID: 24444827]">Tsuji 2014</a>; <a href="./references#CD013202-bbs2-0146" title="VerinaT , FatemiA , JohnstonMV , ComiAM . Pluripotent possibilities: human umbilical cord blood cell treatment after neonatal brain injury. Pediatric Neurology2013;48(5):346-54. [PMID: 23583051]">Verina 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EPC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical vein; human umbilical cord blood; human adipose stem cell; human iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0016"> <li> <p>Umbilical‐cord‐derived EPCs have higher regenerative potential than adult bone marrow‐derived EPCs </p> </li> <li> <p>Endothelial cell protection, repair, angiogenesis</p> </li> <li> <p>Low immunogenicity</p> </li> <li> <p>Paracrine release of regenerative factors</p> </li> <li> <p>Autologous administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0017"> <li> <p>Anti‐inflammatory effects: reduce CD4<sup>+</sup> infiltration to the brain </p> </li> <li> <p>Activation of PI3/Akt pathway</p> </li> <li> <p>Axonal growth: BDNF secretion</p> </li> <li> <p>Angiogenesis: VEGF, IGF‐1 secretion</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0018"> <li> <p>Improve cognitive and motor function</p> </li> <li> <p>Inhibit neuronal apoptosis</p> </li> <li> <p>Stimulate blood vessel formation and reduce infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0059" title="GrandvuilleminI , GarrigueP , RamdaniA , BoubredF , SimeoniU , Dignat-GeorgeF , et al. Long-term recovery after endothelial colony-forming cells or human umbilical cord blood cells administration in a rat model of neonatal hypoxic-ischemic encephalopathy. Stem Cells Translational Medicine2017;6(11):1987-96. [PMID: 28980775]">Grandvuillemin 2017</a>; <a href="./references#CD013202-bbs2-0078" title="KidaniY , MikiY , NomimuraN , MinakawaS , TanakaN , MiyoshiH , et al. The therapeutic effect of CD133(+) cells derived from human umbilical cord blood on neonatal mouse hypoxic-ischemic encephalopathy model. Life Sciences2016;157:108-15. [PMID: 27287679]">Kidani 2016</a>; <a href="./references#CD013202-bbs2-0089" title="McDonaldCA , PennyTR , PatonMC , SutherlandAE , NekkantiL , YawnoT , et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. Journal of Neuroinflammation2018;15(1):47. [PMID: 29454374]">McDonald 2018</a>; <a href="./references#CD013202-bbs2-0096" title="NabetaniM , ShintakuH , HamazakiT . Future perspectives of cell therapy for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2018;83(1-2):356-63. [PMID: 29016557]">Nabetani 2018</a>; <a href="./references#CD013202-bbs2-0151" title="WangJ , ChenY , YangY , XiaoX , ChenS , ZhangC , et al. Endothelial progenitor cells and neural progenitor cells synergistically protect cerebral endothelial cells from Hypoxia/reoxygenation-induced injury via activating the PI3K/Akt pathway. Molecular Brain2016;9:12. [PMID: 26842559]">Wang 2016</a>; <a href="./references#CD013202-bbs2-0155" title="WuCC , ChenYC , ChangYC , WangLW , LinYC , ChiangYL , et al. Human umbilical vein endothelial cells protect against hypoxic-ischemic damage in neonatal brain via stromal cell-derived factor 1/C-X-C chemokine receptor type 4. Stroke2013;44(5):1402-9. [PMID: 23449265]">Wu 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin fibroblasts, umbilical cord tissue, amniotic tissue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0019"> <li> <p>Autologous administration</p> </li> <li> <p>Differentiation into multiple neural lineage cells</p> </li> <li> <p>Low immunogenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0020"> <li> <p>Differentiate into functional neural cells (electrophysiological properties)</p> </li> <li> <p>Decrease infiltration of MPO+ neutrophils and CD11b+ microglia</p> </li> <li> <p>VEGF expression and organelle transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013202-list-0021"> <li> <p>Improve survival and sensorimotor function</p> </li> <li> <p>Establish axonal connections</p> </li> <li> <p>Inhibit inflammation, neural apoptosis, and glial scar formation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013202-bbs2-0032" title="CaiJ , LiW , SuH , QinD , YangJ , ZhuF , et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. Journal of Biological Chemistry2010;285(15):11227-34.">Cai 2010</a>; <a href="./references#CD013202-bbs2-0069" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013202-bbs2-0103" title="OkiK , TatarishviliJ , WoodJ , KochP , WattananitS , MineY , et al. Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells (Dayton, Ohio)2012;30(6):1120-33. [PMID: 22495829]">Oki 2012</a>; <a href="./references#CD013202-bbs2-0117" title="PluchinoS , Peruzzotti-JamettiL . Rewiring the ischaemic brain with human-induced pluripotent stem cell-derived cortical neurons. Brain2013;136(Pt 12):3525-7. [PMID: 24335051]">Pluchino 2013</a>; <a href="./references#CD013202-bbs2-0120" title="QinJ , MaX , QiH , SongB , WangY , WenX , et al. Transplantation of induced pluripotent stem cells alleviates cerebral inflammation and neural damage in hemorrhagic stroke. PloS One2015;10(6):e0129881. [PMID: 26086994]">Qin 2015</a>; <a href="./references#CD013202-bbs2-0140" title="TorneroD , WattananitS , Gronning MadsenM , KochP , WoodJ , TatarishviliJ , et al. Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery. Brain2013;136(Pt 12):3561-77. [PMID: 24148272]">Tornero 2013</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>BDNF: brain‐derived neurotrophic factor; CNS: central nervous system; ESC: embryonic stem cell; EGF: epidermal growth factor; GDNF: glial cell‐line derived neurotrophic factor; HGF: hepatocyte growth factor; HLA: human leukocyte antigen; HSC: haematopoietic stem cells; IGF‐1: insulin‐like growth factor 1; iPSC: inducible pluripotent stem cells; IL: interleukin; MHC: major histocompatibility complex; MSC: mesenchymal stem cell; MNC: mononuclear cells; NF‐κB: nuclear factor kappa beta; NGF: nerve growth factor; NSC: neural stem cells; OPC: oligodendrocyte progenitor cells; RCT: randomised controlled trial; TNF: tumour necrosis factor; VEGF: vascular endothelial growth factor. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of regenerative cells</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013202.pub2/full#CD013202-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013202.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013202-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013202-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013202-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013202-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013202-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013202-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013202-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013202-note-0003">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013202-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013202\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013202\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013202\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013202\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013202.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013202.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013202.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013202.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013202.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725163781"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013202.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725163787"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013202.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e748acfc81be5',t:'MTc0MDcyNTE2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 